

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization

International Bureau



(10) International Publication Number

WO 2017/109180 A1

(43) International Publication Date

29 June 2017 (29.06.2017)

(51) International Patent Classification:

C07K 16/28 (2006.01) A61P 7/04 (2006.01)
C07K 16/36 (2006.01) A61K 39/395 (2006.01)

(21) International Application Number:

PCT/EP2016/082572

(22) International Filing Date:

23 December 2016 (23.12.2016)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

15202582.1 23 December 2015 (23.12.2015) EP

(71) Applicant: JULIUS-MAXIMILIANS-UNIVERSITÄT
WÜRZBURG [DE/DE]; Am Sanderring 2, 97070
Würzburg (DE).

(72) Inventors: NIESWANDT, Bernhard; Am Morgenroth 6,
97246 Eibelstadt (DE). BECK, Sarah; Rennweger Ring
13, 97070 Würzburg (DE). STEGNER, David;
Koppbergweg 18, 97080 Würzburg (DE).

(74) Agents: KALHAMMER, Georg et al.; Unsöldstr. 2,
80538 München (DE).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,

AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY,
BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN,
KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA,
MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG,
NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS,
RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY,
TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN,
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ,
TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU,
TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE,
DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU,
LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK,
SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))



WO 2017/109180 A1

(54) Title: GLYCOPROTEIN V INHIBITORS FOR USE AS COAGULANTS

(57) Abstract: The present invention relates to an inhibitor of platelet glycoprotein V (GPV) for use as a coagulant, and/or for use in the treatment or prevention of a hemorrhagic condition.

5 Glycoprotein V inhibitors for use as coagulants

BACKGROUND

10 Platelet activation and subsequent thrombus formation at sites of vascular injury is crucial for normal hemostasis, but it can also cause myocardial infarction and stroke (Coughlin SR. *Nature*. 2000; **407**: 258-64). Platelet adhesion and activation is a multistep process involving multiple platelet receptor-ligand interactions. Upon vessel wall injury, circulating platelets are rapidly decelerated by transient interactions of the glycoprotein (GP) Ib-V-IX complex with
15 von Willebrand factor (vWF) immobilized on the exposed subendothelial extracellular matrix (e.g. on collagen) (Shapiro MJ, et al. *JBC*. 2000; **275**: 25216-21). This interaction retains platelets close to the vessel wall and facilitates the contact between GPVI and collagen (Nieswandt B, et al. *Blood*. 2003; **102**: 449-61.). GPVI-collagen interactions induce an intracellular signaling cascade leading to platelet activation and the release of secondary
20 platelet agonists, such as thromboxane A₂ (TxA₂) and adenosine diphosphate (ADP). These soluble agonists together with locally produced thrombin further contribute to platelet activation through G protein (G_i, G_q, G_{12/13}) coupled receptors (Offermanns S. *Circulation research*. 2006; **99**: 1293-304). All these signaling pathways synergize to induce complex cellular responses, such as activation of integrins, release of granule contents and the
25 provision of a pro-coagulant surface for the activation of the coagulation cascade (Nakanishi-Matsui M, et al. *Nature*. 2000; **404**: 609-13; Cunningham MA, et al. *J Exp Med* 2000; **191**: 455-62). The final thrombus is embedded in a fibrin network to withstand the shear forces generated by the flowing blood. The stabilization of a newly formed thrombus is essential to arrest bleeding at sites of vascular injury.

30

Their central role in platelet adhesion puts two receptor complexes in the focus of platelet research: i) the GPIb-V-IX complex which interacts with vWF immobilized on the injured vessel wall or on activated platelets and thereby recruits platelets from the blood stream to the reactive surface under conditions of elevated shear. ii) GPIIb/IIIa (integrin α IIb β 3), a
35 receptor for fibrinogen and vWF that requires inside-out activation mediated by agonist receptors, contributes to firm shear-resistant platelet adhesion and is essential for aggregate

formation. The GPIb-V-IX complex is composed of 4 related transmembrane GPs: GPIb α , GPIb β , GPV and GPIX, which are associated in a stoichiometry of 2:4:2:1(Luo S.-Z. et al., *Blood*. 2007; 109(2): 603-9). Within this complex, GPIb α and GPIb β are disulfide-linked and noncovalently associated with GPIX. GPV is noncovalently associated with GPIb-IX

5 (Nieswandt B, et al. *J Thromb Haemost*. 2009; 7: 206-9). Approximately 30,000 copies of the GPIb-IX complex are found on the surface of human platelets (Varga-Szabo D, et al. *J Thromb Haemost*. 2009; 7: 1057-66). Loss of GPIb-V-IX function causes Bernard-Soulier syndrome (BSS), a severe bleeding disorder. BSS is characterized by abnormal, giant circulating platelets with defective adhesion to vWF and reduced thrombin responsiveness
10 (Canobbio I, et al. *Cellular signalling*. 2004; 16: 1329-44). While lack or dysfunction of GPIb or GPIX are associated with BSS, no loss of function mutation in GP5 has been reported and the lack of GPV in mice does not lead to a BSS-phenotype (Ramakrishnan V, et al. *PNAS*. 1999; 96: 13336-41; Kahn ML, et al. *Blood*. 1999; 94: 4112-21). GPV is the only subunit
15 which is not required for the correct expression of the complex (Dong J-f, et al. *J Biol Chem*. 1998; 273: 31449-54). GPV is highly glycosylated and contains a thrombin cleavage site leading to quantitative removal of GPV from the platelet surface and the generation of soluble GPV (sGPV) in the presence of thrombin (Ravanat C, et al. *Blood*. 1997; 89: 3253-62; Azorsa DO, et al. *Thrombosis and Haemostasis*. 1999; 81: 131-8). Of note, this thrombin cleavage site is conserved in the mouse, rat and human protein (Ravanat C, et al. *Blood*.
20 1997; 89: 3253-62). However, in contrast to protease-activated receptor (PAR) 4-deficient mice, which do not respond upon thrombin stimulation (Kahn ML, et al. *Blood*. 1999; 94: 4112-21; Kahn ML, et al. *Nature*. 1998; 394: 690-4.), *Gp5*^{-/-} mice display grossly normal platelet functionality.

25 *In vitro*, *Gp5*^{-/-} platelets are hardly distinguishable from wildtype platelets (Ramakrishnan V, et al. *PNAS*. 1999; 96: 13336-41; Kahn ML, et al. *Blood*. 1999; 94: 4112-21). Only after activation with threshold doses of thrombin, an increased responsiveness was observed (Ramakrishnan V, et al. *PNAS*. 1999; 96: 13336-41), which has been ascribed to the lack of GPV as an alternative substrate for thrombin competing with PARs. For one of the two *Gp5*^{-/-}
30 mouse strains, reduced tail bleeding times, accelerated thrombus formation and increased embolization were reported (Ramakrishnan V, et al. *PNAS*. 1999; 96: 13336-41; Ni H, et al. *Blood*. 2001; 98: 368-73), whereas analysis of the second mouse line revealed unaltered tail bleeding times and impaired thrombus formation (Kahn ML, et al. *Blood*. 1999; 94: 4112-21; Moog S, et al. *Blood*. 2001; 98: 1038-46). The latter group ascribed the defective thrombus
35 formation to the role of GPV in collagen signaling, thereby establishing collagen as ligand for GPV (Moog S, et al. *Blood*. 2001; 98: 1038-46). The latest report on *Gp5*^{-/-} mice used mice

backcrossed to the C57Bl/6 background and confirmed the increased thrombin responsiveness as well as slightly reduced adhesion on collagen. Using laser-injury, the authors demonstrated that the effect of GPV-deficiency on thrombus formation depends on the severity of the injury and concluded that GPV is only of minor relevance for arterial 5 thrombus formation (Nonne C, et al. *J Thromb Haemost.* 2008; **6**: 210-2). So far, the role of GPV in thrombosis and hemostasis seems to be of minor relevance for maintaining hemostasis and platelet function. However, the exact function of GPV in thrombosis, hemostasis and thrombo-inflammatory brain infarction still remains poorly understood.

10 SUMMARY OF THE INVENTION

The inventors surprisingly found that mice treated with an antibody directed against a region of the extracellular domain of GPV which is distinct from the collagen-binding site of GPV displayed an accelerated time to thrombus formation *in vivo*. In addition, antibody-mediated 15 blockade of GPV could fully compensate for the lack of GPVI in *in vivo* thrombus formation and hemostasis.

The present invention therefore relates to the following embodiments [1] to [28]:

- 20 [1] An inhibitor of glycoprotein V (platelet glycoprotein V; GPV) for use as a coagulant.
- [2] An inhibitor of glycoprotein V (platelet glycoprotein V; GPV) for use in the treatment or prevention of a hemorrhagic condition.
- 25 [3] The inhibitor for use according to embodiment [2], wherein said hemorrhagic condition is caused by a platelet disorder.
- [4] The inhibitor for use according to embodiment [3], wherein said platelet disorder is characterized by a decreased number of platelets.
- 30 [5] The inhibitor for use according to embodiment [3] or [4], wherein the platelet disorder is thrombocytopenia, e.g. idiopathic thrombocytopenic purpura, thrombotic thrombocytopenic purpura, thrombocytopenia caused by chemotherapy, or immunothrombocytopenia.

[6] The inhibitor for use according to any one of embodiments [2] to [4], wherein said hemorrhagic condition is selected from the group consisting of inflammatory bleeding, hemorrhagic stroke, excessive bleeding due to sepsis, excessive bleeding due to thrombocytopenia, excessive bleeding due to disseminated intravascular coagulation (DIC), excessive bleeding due to chemotherapy, excessive bleeding due to hemolytic-uremic syndrome, excessive bleeding upon administration of soluble GPV, and excessive bleeding due to HIV infection.

[7] The inhibitor for use according to any one of the preceding embodiments, wherein said GPV is human GPV.

[8] The inhibitor for use according to embodiment [7], wherein said human GPV comprises or consists of the amino acid sequence as shown in SEQ ID NO:3.

[9] The inhibitor for use according to any one of the preceding embodiments, wherein said inhibitor is a polypeptide.

[10] The inhibitor for use according to embodiment [9], wherein said inhibitor is (i) an antibody capable of binding to the extracellular domain of GPV, (ii) a fragment or derivative of an antibody, said fragment or derivative being capable of binding to the extracellular domain of GPV, (iii) an antibody capable of binding to an epitope within the extracellular domain of GPV, or (iv) a fragment or derivative of an antibody, said fragment or derivative being capable of binding to an epitope within the extracellular domain of GPV.

25

[11] The inhibitor for use according to embodiment [10], wherein said extracellular domain comprises or consists of amino acids 1 to 503 of SEQ ID NO:3.

[12] The inhibitor for use according to embodiment [10] or [11], wherein said antibody, fragment or derivative binds to a region of the extracellular domain of GPV which is different from the collagen-binding site of GPV.

[13] The inhibitor for use according to any one of the embodiments [10] to [12], wherein said antibody, fragment or derivative does not delay collagen-induced aggregation.

35

[14] The inhibitor for use according to any one of the embodiments [10] to [13], wherein said epitope is outside the collagen-binding site of GPV and/or does not overlap with the collagen-binding site of GPV.

5 [15] The inhibitor for use according to any one of the embodiments [10] to [14], wherein said antibody is a monoclonal antibody or a functional fragment or functional derivative thereof.

10 [16] The inhibitor for use according to any one of the preceding embodiments, wherein said inhibitor is a nucleic acid.

[17] The inhibitor for use according to embodiment [16], wherein said nucleic acid is capable of reducing expression of GPV.

15 [18] The inhibitor for use according to embodiment [17], wherein said nucleic acid is selected from the group consisting of antisense nucleic acid, siRNA and shRNA.

[19] The inhibitor for use according to embodiment [16], wherein said nucleic acid is capable of binding to the extracellular domain of GPV.

20 [20] The inhibitor for use according to embodiment [19], wherein said nucleic acid is an aptamer.

25 [21] The inhibitor for use according to any one of the preceding embodiments, wherein said inhibitor, upon administration to a subject, does not substantially affect the number of platelets in said subject.

[22] The inhibitor for use according to any one of the embodiments [2] to [21], wherein said inhibitor is used as a coagulant.

30 [23] The inhibitor for use according to any one of the embodiments [2] to [22], wherein said treatment or prevention comprises administering to a subject, preferably to a human, a pharmaceutically effective amount of said inhibitor.

[24] The inhibitor for use according to embodiment [23], wherein said treatment or prevention further comprises administering to said subject a coagulant other than said inhibitor.

5 [25] The inhibitor for use according to embodiment [24], wherein said coagulant other than said inhibitor is selected from the group consisting of an anti-fibrinolytic agent, a platelet concentrate, a coagulation factor concentrate and fresh frozen plasma.

10 [26] A pharmaceutical composition comprising an inhibitor as defined in any one of the preceding embodiments, and a pharmaceutically acceptable excipient.

[27] A pharmaceutical composition as defined in embodiment [26] for use in the treatment or prevention of a hemorrhagic condition.

15 [28] A method of treating a hemorrhagic condition in a subject, preferably a human, comprising administering to the subject an effective amount of an inhibitor as defined in any one of embodiments [1] to [21], or of the pharmaceutical composition of embodiment [26].

20 BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1: The monoclonal anti-GPV antibody 89F12 binds to the extracellular domain of GPV. (A) 89F12-FITC binds to WT, but not to GPV-deficient platelets as assessed by flow cytometry. (B) 89F12-HRP detects recombinant murine sGPV in an ELISA system.

25

Figure 2: The monoclonal anti-GPV antibody 89F12 binds to the extracellular domain of GPV without affecting platelet count and thrombin-mediated cleavage of GPV. (A, B) 100 µg 89F12 was injected intravenously and afterwards, platelet count as well as GPV surface expression were analyzed. (C) The antibody 89F12 does not affect the thrombin-mediated cleavage of GPV as assessed by flow cytometry. (D) 89F12 does not alter $\alpha IIb\beta 3$ integrin-mediated platelet activation and P-selectin exposure in response to thrombin.

30

Figure 3: 89H11, but not 89F12, blocks the collagen-binding site on GPV. Washed murine platelets from mice lacking the collagen-binding integrin $\alpha 2\beta 1$ (*Itga2^{-/-}*) were 35 stimulated with 2 µg/ml fibrillar collagen in the presence of vehicle (black curve) or the anti-

GPV antibodies 89H11 (light grey) or 89F12 (dark grey). Displayed are representative aggregometry curves of 2 independent experiments with four mice per group each.

Figure 4: The antibody 89F12 propagates hemostasis in wildtype mice and restores it

5 **in GPVI/CLEC-2 double-deficient animals.** Displayed are tail bleeding times of the indicated mouse lines. Each symbol represents one animal. In cases where mice were unable to arrest bleeding Fisher's exact test was used to calculate *P*-values.

Figure 5: The antibody 89F12 restores hemostasis in GPVI/ITGA2 double-deficient

10 **mice.** Displayed are tail bleeding times of the indicated mouse lines. Each symbol represents one animal. In cases where mice were unable to arrest bleeding Fisher's exact test was used to calculate *P*-values.

Figure 6: The monoclonal anti-GPV antibody 89F12 compensates for the lack of GPVI

15 **in an *in vivo* thrombus formation model.** Mesenteric arterioles were injured with 20% FeCl₃ and adhesion and thrombus formation of fluorescently-labeled platelets were monitored by intravital microscopy. Each dot represents one vessel, horizontal lines indicate the median. * *P*<0.05; ** *P*<0.01; *** *P*<0.001.

20 Figure 7: The antibody 89F12 can compensate for the lack of RhoA in hemostasis.

Displayed are tail bleeding times of the indicated mouse lines. Each symbol represents one animal, horizontal lines indicate the median (not depicted if the median would have been above 1200 s). In cases where mice were unable to arrest bleeding Fisher's exact test was used to calculate *P*-values. * *P*<0.05; ** *P*<0.01.

25

DETAILED DESCRIPTION

The present invention relates to an inhibitor of platelet glycoprotein V (GPV) for use as a coagulant, and/or to an inhibitor of GPV for use in the treatment or prevention of a

30 hemorrhagic condition.

Glycoprotein V

The term "Glycoprotein V" or "GPV", as used herein, denotes a membrane protein having a

35 sequence identity of at least 50% to the amino acid sequence as shown in SEQ ID NO:3. Preferably, the GPV has an amino acid identity of at least 60%, or at least 70%, or at least

80%, or at least 90%, or at least 95% to the amino acid sequence as shown in SEQ ID NO:3. The GPV has a functional transmembrane domain.

In accordance with the present invention, a sequence being evaluated (the "Compared Sequence") has a certain "percent identity with", or is certain "percent identical to" a claimed or described sequence (the "Reference Sequence") after alignment of the two sequences. The "Percent Identity" is determined according to the following formula:

Percent Identity=100[1-(C/R)]

10

In this formula, C is the number of differences between the Reference Sequence and the Compared Sequence over the length of alignment between the two sequences wherein (i) each base in the Reference Sequence that does not have a corresponding aligned base in the Compared Sequence, and (ii) each gap in the Reference Sequence, and (iii) each aligned base in the Reference Sequence that is different from an aligned base in the Compared Sequence constitutes a difference. R is the number of bases of the Reference Sequence over the length of the alignment with the Compared Sequence with any gap created in the Reference Sequence also being counted as a base.

20

If an alignment exists between the Compared Sequence and the Reference Sequence for which the Percent Identity (calculated as above) is about equal to, or greater than, a specified minimum, the Compared Sequence has that specified minimum Percent Identity even if alignments may exist elsewhere in the sequence that show a lower Percent Identity than that specified.

25

In a preferred embodiment, the length of aligned sequence for comparison purposes is at least 30%, preferably at least 40%, more preferably at least 50%, even more preferably at least 60%, and even more preferably at least 70%, 80%, or 90% of the length of the Reference Sequence.

30

The comparison of sequences and determination of percent identity (and percent similarity) between two amino acid sequences can be accomplished using any suitable program, e.g. the program "BLAST 2 SEQUENCES (blastp)" (Tatusova et al. *FEMS Microbiol. Lett.* 1999; 174: 247-250) with the following parameters: Matrix BLOSUM62; Open gap 11 and extension gap 1 penalties; gap x_dropoff50; expect 10.0 word size 3; Filter: none. According to the present invention, the sequence comparison covers at least 40 amino acids, preferably

at least 80 amino acids, more preferably at least 100 amino acids, and most preferably at least 120 amino acids.

The GPV referred to herein typically is platelet glycoprotein V.

5

Typically, the GPV is a naturally occurring GPV. Preferably, the GPV is of mammalian origin. Most preferably, the GPV is a human GPV. According to this embodiment, the GPV preferably comprises or consists of the amino acid sequence as shown in SEQ ID NO:3.

10 *Inhibitors of GPV*

An inhibitor of GPV (hereinafter referred to as "GPV inhibitor") is a compound which (i) has pro-coagulatory activity and (ii) is capable of binding to the extracellular domain of GPV, or of attenuating expression of GPV mRNA. Preferably, the GPV inhibitor is a compound which (i)

15 has pro-coagulatory activity and (ii) is capable of binding to the extracellular domain of GPV. In accordance with this invention, pro-coagulatory activity is determined in a "Bleeding Time Assay" as described in the examples, with the proviso that the mouse used in the Bleeding Time Assay is a transgenic mouse lacking endogenous GPV and expressing human GPV. Binding to the extracellular domain of GPV can be determined in an ELISA as described in
20 the examples. In one embodiment, binding to the extracellular domain of GPV is determined in an ELISA using recombinant soluble GPV, as depicted in Figure 1B, with the proviso that recombinant soluble *human* GPV is used. Most preferably, binding to the extracellular domain of GPV is determined in an ELISA using recombinant soluble GPV, as depicted in Figure 1B, with the proviso that recombinant soluble human GPV substantially consisting of
25 amino acids 1-503 of SEQ ID NO:3 is used.

The GPV inhibitor may affect, e.g. inhibit, the thrombin-mediated cleavage of GPV in a subject upon administration of the GPV inhibitor to the subject. In another embodiment, the GPV inhibitor does not affect the thrombin-mediated cleavage of GPV in a subject upon
30 administration of the GPV inhibitor to the subject.

The type or class of the GPV inhibitor is not particularly limited. Preferably, however, the compound is a peptide or polypeptide, more preferably the compound is an antibody or a fragment thereof. In yet another embodiment, the GPV inhibitor is a nucleic acid.

Antibodies

In a preferred embodiment, the GPV inhibitor is an antibody. The term "antibody", as used herein, refers to an immunoglobulin molecule that binds to or is immunologically reactive with

5 a particular antigen, and includes polyclonal, monoclonal, genetically engineered and otherwise modified forms of antibodies including, but not limited to, chimeric antibodies, humanized antibodies, human antibodies, heteroconjugate antibodies (e.g. bispecific antibodies, diabodies, triabodies, and tetrabodies), single-domain antibodies (nanobodies) and antigen binding fragments of antibodies, including e.g. Fab', F(ab')2, Fab, Fv, rlgG, and
10 scFv fragments. Moreover, unless otherwise indicated, the term "monoclonal antibody" (mAb) is meant to include both intact molecules, as well as, antibody fragments (such as, for example, Fab and F(ab')2 fragments) which are capable of binding to a protein. Fab and F(ab')2 fragments lack the Fc fragment of intact antibody, clear more rapidly from the circulation of the animal, and may have less non-specific tissue binding than an intact
15 antibody (Wahl et al. *J. Nucl. Med.* 1983; **24**: 316).

Typically, the antibody is capable of binding to the extracellular domain of GPV, preferably of human GPV. Whether a molecule or an antibody is capable of binding to the extracellular domain of GPV can be determined by a binding assay described in Example/Figure 1A or 1B
20 (see below).

The antibody, fragment or derivative referred to herein preferably binds to a region within the extracellular domain of GPV which is distinct from the collagen-binding site of GPV. In another embodiment, the antibody, fragment or derivative does not delay collagen-induced
25 aggregation. This can be determined in an aggregation assay as described in the Examples (see Figure 3 and materials and methods).

Further preferred inhibitors are antibodies, fragments and derivatives thereof which compete with antibody 89F12 for binding to human GPV. Further preferred inhibitors are antibodies, fragments and derivatives thereof which bind to an epitope on GPV which overlaps with the epitope on GPV of antibody 89F12. Further preferred inhibitors are antibodies, fragments and derivatives thereof which bind to the same epitope on GPV as antibody 89F12.
30

In other embodiments, the inhibitor is an antibody, fragment or derivative thereof which does
35 not compete with antibody 89H11 for binding to human GPV. In another embodiment, the inhibitor is an antibody, fragment or derivative thereof which binds to an epitope on GPV

which does not overlap with the epitope on GPV of antibody 89H11. In yet another embodiment, the inhibitor is an antibody, fragment or derivative thereof which binds to an epitope on GPV which is different from the epitope on GPV of antibody 89H11.

In other embodiments, the inhibitor is an antibody, fragment or derivative thereof which does

5 not compete with antibody V.3 (Azorsa DO, et al. *Thrombosis and Haemostasis*. 1999; **81**: 131-8; Moog S, et al. *Blood*. 2001; **98**: 1038-46) for binding to human GPV. In another embodiment, the inhibitor is an antibody, fragment or derivative thereof which binds to an epitope on GPV which does not overlap with the epitope on GPV of antibody V.3. In yet another embodiment, the inhibitor is an antibody, fragment or derivative thereof which binds

10 to an epitope on GPV which is different from the epitope on GPV of antibody V.3.

The embodiments in the preceding paragraphs can be combined with each other.

The antibody preferably binds to an epitope within amino acids 1-503 of SEQ ID NO:3. For

15 example, the present invention includes, but is not limited to, the following embodiments:

Table 1.

Embodiment No.	The antibody binds to an epitope within the following amino acids of SEQ ID NO:3
1	1-30
2	16-45
3	31-60
4	46-75
5	61-90
6	76-105
7	91-120
8	106-135
9	121-150
10	136-165
11	151-180
12	166-195
13	181-210
14	196-225
15	211-240

Embodiment No.	The antibody binds to an epitope within the following amino acids of SEQ ID NO:3
16	226-255
17	241-270
18	256-285
19	271-300
20	286-315
21	301-330
22	316-345
23	331-360
24	346-375
25	361-390
26	376-405
27	391-420
28	406-435
29	421-450
30	436-465
31	451-480
32	466-495
33	481-503

The dissociation constant K_D for the complex formed by the extracellular domain of GPV and antibody is preferably less than 100 μM , more preferably less than 10 μM , most preferably less than 5 μM . Typically the K_D ranges from about 1 pM to about 10 μM , or from about 10 pM to about 1 μM , or from about 100 pM to about 100 nM. Preferably, the antibody-GPV complex has a K_D in the range from 5 pM to 1 nM, most preferably from 10 pM to 500 pM.

Preferably, the antibody is a monoclonal antibody. The term "monoclonal antibody" as used herein is not limited to antibodies produced through hybridoma technology. The term "monoclonal antibody" refers to an antibody that is derived from a single clone, including any eukaryotic, prokaryotic, or phage clone, and not the method by which it is produced. Monoclonal antibodies can be prepared using a wide variety of techniques known in the art including the use of hybridoma, recombinant, and phage display technologies, or a

combination thereof (Harlow and Lane, "Antibodies, A Laboratory Manual" CSH Press 1988, Cold Spring Harbor N.Y.).

In other embodiments, including *in vivo* use of the anti-GPV antibodies in humans, chimeric,

5 primatized, humanized, or human antibodies can be used. In a preferred embodiment, the antibody is a human antibody or a humanized antibody, more preferably a monoclonal human antibody or a monoclonal humanized antibody.

The term "chimeric" antibody as used herein refers to an antibody having variable sequences

10 derived from non-human immunoglobulins, such as rat or mouse antibodies, and human immunoglobulins constant regions, typically chosen from a human immunoglobulin template.

Methods for producing chimeric antibodies are known in the art. See, e.g. Morrison. *Science*.

1985; **229**(4719): 1202-7; Oi et al. *BioTechniques*. 1986; **4**: 214-221; Gillies et al. *J. Immunol.*

Methods 1985; **125**: 191-202; US 5,807,715; US 4,816,567; and US 4,816,397, which are

15 incorporated herein by reference in their entireties.

"Humanized" forms of non-human (e.g. murine) antibodies are chimeric immunoglobulins,

immunoglobulin chains or fragments thereof (such as Fv, Fab, Fab', F(ab')2 or other target-binding subsequences of antibodies), which contain minimal sequences derived from a non-

20 human immunoglobulin. In general, the humanized antibody will comprise substantially all of at least one and typically two variable domains, in which all or substantially all of the complementarity determining regions (CDRs) correspond to those of a non-human immunoglobulin and all or substantially all of the framework (FR) regions are those of a human immunoglobulin consensus sequence. The humanized antibody can also comprise at

25 least a portion of an immunoglobulin constant region (Fc), typically that of a human immunoglobulin template chosen. Humanization is a technique for making a chimeric antibody in which one or more amino acids or portions of the human variable domain have been substituted by the corresponding sequence from a non-human species. Humanized antibodies are antibody molecules generated in a non-human species that bind the desired

30 antigen having one or more CDRs from the non-human species and FRs from a human immunoglobulin molecule. Often, framework residues in the human framework regions will be substituted with the corresponding residue from the CDR donor antibody to alter, preferably improve, antigen binding. These framework substitutions are identified by methods well known in the art, e.g. by modeling of the interactions of the CDR and framework residues to

35 identify framework residues important for antigen binding and sequence comparison to identify unusual framework residues at particular positions. See, e.g. Riechmann et al.

Nature 1988; **332**: 323-7 and Queen et al. US 5,530,101; US 5,585,089; US 5,693,761; US 5,693,762; and US 6,180,370 (each of which is incorporated by reference in its entirety). Antibodies can be humanized using a variety of techniques known in the art including, for example, CDR-grafting (EP239400; WO 91/09967; US 5,225,539; US 5,530,101 and US

5 5,585,089), veneering or resurfacing (EP0592106; EP0519596; Padlan. *Mol Immunol.* 1991; **28**: 489-498; Studnicka et al. *Prot Eng.* 1994; **7**: 805-814; Roguska et al. *PNAS* 1994; **91**: 969-973, and chain shuffling (US 5,565,332)), all of which are hereby incorporated by reference in their entireties.

10 In some embodiments, humanized antibodies are prepared as described in Queen et al., US 5,530,101; US 5,585,089; US 5,693,761; US 5,693,762; and US 6,180,370 (each of which is incorporated by reference in its entirety).

In some embodiments, the anti-GPV antibodies are human antibodies. Completely "human"

15 anti-GPV antibodies can be desirable for therapeutic treatment of human patients. As used herein, "human antibodies" include antibodies having the amino acid sequence of a human immunoglobulin and include antibodies isolated from human immunoglobulin libraries or from animals transgenic for one or more human immunoglobulin and that do not express endogenous immunoglobulins. Human antibodies can be made by a variety of methods

20 known in the art including phage display methods described above using antibody libraries derived from human immunoglobulin sequences. See US 4,444,887 and US 4,716,111; and WO 98/46645; WO 98/50433; WO 98/24893; WO 98/16654; WO 96/34096; WO 96/33735; and WO 91/10741, each of which is incorporated herein by reference in its entirety. Human antibodies can also be produced using transgenic mice which are incapable of expressing

25 functional endogenous immunoglobulins, but which can express human immunoglobulin genes. See, e.g. WO 98/24893; WO 92/01047; WO 96/34096; WO 96/33735; US 5,413,923; US 5,625,126; US 5,633,425; US 5,569,825; US 5,661,016; US 5,545,806; US 5,814,318; US 5,885,793; US 5,916,771; and US 5,939,598, which are incorporated by reference herein in their entireties. Completely human antibodies that recognize a selected epitope can be

30 generated using a technique referred to as "guided selection." In this approach a selected non-human monoclonal antibody, e.g. a mouse antibody, is used to guide the selection of a completely human antibody recognizing the same epitope (Jespers et al. *Biotechnology*. 1988; **12**: 899-903).

35 In some embodiments, the anti-GPV antibodies are primatized antibodies. The term "primatized antibody" refers to an antibody comprising monkey variable regions and human

constant regions. Methods for producing primatized antibodies are known in the art. See e.g. US 5,658,570; US 5,681,722; and US 5,693,780, which are incorporated herein by reference in their entireties.

5 In some embodiments, the anti-GPV antibodies are derivatized antibodies. For example, but not by way of limitation, the derivatized antibodies that have been modified, e.g. by glycosylation, acetylation, pegylation, phosphorylation, amidation, derivatization by known protecting/blocking groups, proteolytic cleavage or linkage to a cellular ligand or other proteins (see *below* for a discussion of antibody conjugates). Any of numerous chemical
10 modifications may be carried out by known techniques, including, but not limited to, specific chemical cleavage, acetylation, formylation or metabolic synthesis of tunicamycin, etc. Additionally, the derivative may contain one or more non-classical amino acids.

15 In some embodiments, the anti-GPV antibodies or fragments thereof can be antibodies or antibody fragments, whose sequence has been modified to reduce at least one constant region-mediated biological effector function relative to the corresponding wild type sequence. To modify an anti-GPV antibody, such that it exhibits reduced binding to the Fc receptor, the immunoglobulin constant region segment of the antibody can be mutated at particular regions necessary for Fc receptor (FcR) interactions (see, e.g. Canfield and Morrison. *J Exp
20 Med.* 1991; **173**: 1483- 1491; and Lund et al. *J Immunol.* 1991; **147**: 2657-2662). Reduction in FcR binding ability of the antibody can also reduce other effector functions which rely on FcR interactions, such as opsonization, phagocytosis and antigen-dependent cellular cytotoxicity.

25 In yet another aspect, the anti-GPV antibodies or fragments thereof can be antibodies or antibody fragments that have been modified to increase or reduce their binding affinities to the fetal Fc receptor, FcRn. To alter the binding affinity to FcRn, the immunoglobulin constant region segment of the antibody can be mutated at particular regions necessary for FcRn interactions (see, e.g. WO 2005/123780). Increasing the binding affinity to FcRn should
30 increase the antibody's serum half-life, and reducing the binding affinity to FcRn should conversely reduce the antibody's serum half-life. Specific combinations of suitable amino acid substitutions are identified in Table 1 of WO 2005/123780, which table is incorporated by reference herein in its entirety. See also, Hinton et al., US 7,217,797, US 7,361,740, US 7,365,168, and US 7,217,798, which are incorporated herein by reference in their entireties.
35 In yet other aspects, an anti-GPV antibody has one or more amino acids inserted into one or more of its hypervariable regions, for example as described in US 2007/0280931.

Antibody Conjugates

In some embodiments, the anti-GPV antibodies are antibody conjugates that are modified,

5 e.g. by the covalent attachment of any type of molecule to the antibody, such that covalent attachment does not interfere with binding to GPV. Techniques for conjugating effector moieties to antibodies are well known in the art (See, e.g. Hellstrom et al., *Controlled Drug Delivery*, 2nd Ed., 623-53 (Robinson et al., eds., 1987); Thorpe et al. *Immunol Rev.* 1982; **62**: 119-58 and Dubowchik et al. *Pharmacology and Therapeutics* 1999; **83**: 67-123).

10

In one example, the antibody or fragment thereof is fused via a covalent bond (e.g. a peptide bond), at optionally the N-terminus or the C-terminus, to an amino acid sequence of another protein (or portion thereof; preferably at least a 10, 20 or 50 amino acid portion of the protein). Preferably, the antibody or fragment thereof is linked to the other protein at the N-15 terminus of the constant domain of the antibody. Recombinant DNA procedures can be used to create such fusions, for example as described in WO 86/01533 and EP 0392745. In another example, the effector molecule can increase half-life *in vivo*. Examples of suitable effector molecules of this type include polymers, albumin, albumin binding proteins or albumin binding compounds, such as those described in WO 2005/117984.

20

In some embodiments, anti-GPV antibodies can be attached to poly(ethyleneglycol) (PEG) moieties. For example, if the antibody is an antibody fragment, the PEG moieties can be attached through any available amino acid side-chain or terminal amino acid functional group located in the antibody fragment, for example any free amino, imino, thiol, hydroxyl or carboxyl group. Such amino acids can occur naturally in the antibody fragment or can be engineered into the fragment using recombinant DNA methods. See, for example US 5,219,996. Multiple sites can be used to attach two or more PEG molecules. Preferably, PEG moieties are covalently linked through a thiol group of at least one cysteine residue located in the antibody fragment. Where a thiol group is used as the point of attachment, appropriately activated effector moieties, for example thiol selective derivatives, such as maleimides and cysteine derivatives, can be used.

In another example, an anti-GPV antibody conjugate is a modified Fab' fragment which is PEGylated, i.e., has PEG (poly(ethyleneglycol)) covalently attached thereto, e.g. according to

35 the method disclosed in EP 0948544. See also *Poly(ethyleneglycol) Chemistry, Biotechnical and Biomedical Applications*, (J. Milton Harris (ed.), Plenum Press, New York, 1992);

Poly(ethyleneglycol) Chemistry and Biological Applications, (J. Milton Harris and S. Zalipsky, eds., American Chemical Society, Washington D. C, 1997); and Bioconjugation Protein Coupling Techniques for the Biomedical Sciences, (M. Aslam and A. Dent, eds., Grove Publishers, New York, 1998); and Chapman. *Advanced Drug Delivery Reviews* 2002; **54**:

5 531- 545.

Nucleic Acids

In other embodiments of the invention, the GPV inhibitor is a nucleic acid. In a particular embodiment, the nucleic acid is capable of attenuating expression of GPV mRNA. Expression of GPV can be inhibited or reduced or abolished by RNA interference, e.g. by using siRNA or shRNA. Another possibility is the use of antisense nucleic acid, e.g. antisense RNA.

15 The phrase "attenuating expression of an mRNA," as used herein, means administering or expressing an amount of interfering RNA (e.g. an siRNA) to reduce translation of the target mRNA into protein, either through mRNA cleavage or through direct inhibition of translation. The reduction in expression of the target mRNA or the corresponding protein is commonly referred to as "knock-down" and is reported relative to levels present following administration

20 or expression of a non-targeting control RNA (e.g. a non-targeting control siRNA). Knock-down of expression of an amount including and between 50% and 100% is contemplated by embodiments herein. However, it is not necessary that such knock-down levels are achieved for purposes of the present invention. Knock-down is commonly assessed by measuring the mRNA levels using quantitative polymerase chain reaction (qPCR) amplification or by 25 measuring protein levels by western blot or enzyme-linked immunosorbent assay (ELISA). Analyzing the protein level provides an assessment of both mRNA cleavage as well as translation inhibition. Further techniques for measuring knock-down include RNA solution hybridization, nuclease protection, northern hybridization, gene expression monitoring with a microarray, antibody binding, radioimmunoassay, and fluorescence activated cell analysis.

30

Inhibition of GPV mRNA expression may also be determined *in vitro* by evaluating GPV mRNA levels or GPV protein levels in, for example, human cells following transfection of GPV-interfering RNA.

35 In one embodiment of the invention, interfering RNA (e.g. siRNA) has a sense strand and an antisense strand, and the sense and antisense strands comprise a region of at least near-

perfect contiguous complementarity of at least 19 nucleotides. In a further embodiment of the invention, interfering RNA (e.g. siRNA) has a sense strand and an antisense strand, and the antisense strand comprises a region of at least near-perfect contiguous complementarity of at least 19 nucleotides to a target sequence of GPV mRNA, and the sense strand comprises

5 a region of at least near-perfect contiguous identity of at least 19 nucleotides with a target sequence of GPV mRNA, respectively. In a further embodiment of the invention, the interfering RNA comprises a region of at least 13, 14, 15, 16, 17, or 18 contiguous nucleotides having percentages of sequence complementarity to or, having percentages of sequence identity with, the penultimate 13, 14, 15, 16, 17, or 18 nucleotides, respectively, of

10 the 3' end of the corresponding target sequence within an mRNA.

The length of each strand of the interfering RNA comprises 19 to 49 nucleotides, and may comprise a length of 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, or 49 nucleotides. The antisense strand of an

15 siRNA is the active guiding agent of the siRNA in that the antisense strand is incorporated into RISC, thus allowing RISC to identify target mRNAs with at least partial complementary to the antisense siRNA strand for cleavage or translational repression. In embodiments of the present invention, interfering RNA target sequences (e.g. siRNA target sequences) within the GPV mRNA sequence are selected using available design tools. Interfering RNAs

20 corresponding to a GPV target sequence are then tested by transfection of cells expressing the target mRNA followed by assessment of knockdown as described above. Techniques for selecting target sequences for siRNAs are provided in "siRNA Design: Methods and Protocols", edited by Debra J. Taxman, 2012 (ISBN-13: 9781627031189).

25 In a second particular embodiment, the nucleic acid is capable of binding to the extracellular domain of human GPV. In accordance with this embodiment, the nucleic acid is preferably an aptamer. Aptamers can be designed as described in "De novo Molecular Design", 2013, edited by Gisbert Schneider, Chapter 21 (ISBN-13: 9783527677030); or in "The Aptamer Handbook: Functional Oligonucleotides and Their Applications", 2006, edited by Sven

30 Klussmann (ISBN-13: 9783527607914).

Hemorrhagic conditions

35 The inhibitor described herein is preferably used in the treatment or prevention of a hemorrhagic condition. Hemorrhagic conditions are characterized by excessive bleeding. The excessive bleeding can have various causes.

In one embodiment, the hemorrhagic condition is caused by a platelet disorder.

The platelet disorder may be characterized by a decreased number of platelets, e.g. in the

5 case of thrombocytopenia. Specific thrombocytopenias include, but are not limited to, idiopathic thrombocytopenic purpura, thrombotic thrombocytopenic purpura, drug-induced thrombocytopenia due to immune-mediated platelet destruction (e.g. by heparin, trimethoprim/sulfamethoxazole), drug-induced thrombocytopenia due to dose-dependent bone marrow suppression (e.g. by chemotherapeutic agents), thrombocytopenia 10 accompanying systemic infection, thrombocytopenia caused by chemotherapy, gestational thrombocytopenia, and immune thrombocytopenia (ITP, formerly called immune thrombocytopenic purpura).

The platelet disorder may be characterized by a dysfunction of the platelets, e.g. in the case

15 of defective platelet signaling due to lack of platelet receptors or signaling molecules.

In a preferred embodiment, the hemorrhagic condition is selected from the group consisting

of inflammatory bleeding, hemorrhagic stroke, excessive bleeding due to sepsis, excessive

20 bleeding due to thrombocytopenia, excessive bleeding due to disseminated intravascular coagulation (DIC), excessive bleeding due to chemotherapy, excessive bleeding due to hemolytic-uremic syndrome, and excessive bleeding due to HIV infection.

In a specific embodiment, the present invention relates to the use of the inhibitor described

herein as antidote for the administration of soluble GPV.

25

Pharmaceutical Compositions and Treatment

Treatment of a disease encompasses the treatment of patients already diagnosed as having

any form of the disease at any clinical stage or manifestation; the delay of the onset or

30 evolution or aggravation or deterioration of the symptoms or signs of the disease; and/or preventing and/or reducing the severity of the disease.

A "subject" or "patient" to whom a GPV inhibitor, e.g. an anti-GPV antibody, is administered

can be a mammal, such as a non-primate (e.g. cow, pig, horse, cat, dog, rat, etc.) or a

35 primate (e.g. monkey or human). In certain aspects, the human is a pediatric patient. In other aspects, the human is an adult patient.

Compositions comprising a GPV inhibitor and, optionally one or more additional therapeutic agents, such as the second therapeutic agents described below, are described herein. The compositions typically are supplied as part of a sterile, pharmaceutical composition that

5 includes a pharmaceutically acceptable carrier. This composition can be in any suitable form (depending upon the desired method of administering it to a patient).

The GPV inhibitors, e.g. the anti-GPV antibodies, can be administered to a patient by a variety of routes such as orally, transdermally, subcutaneously, intranasally, intravenously,

10 intramuscularly, intrathecally, topically or locally. The most suitable route for administration in any given case will depend on the particular antibody, the subject, and the nature and severity of the disease and the physical condition of the subject. Typically, a GPV inhibitor, e.g. an anti-GPV antibody, will be administered intravenously.

15 Another aspect of the invention is a pharmaceutical composition comprising the antibody or antigen-binding fragment thereof of the invention. The antibody or antigen-binding fragment thereof can be formulated according to known methods for preparing a pharmaceutical composition. For example, it can be mixed with one or more pharmaceutically acceptable carriers, diluents or excipients. For example, sterile water or physiological saline may be 20 used. Other substances, such as pH buffering solutions, viscosity reducing agents, or stabilizers may also be included.

A wide variety of pharmaceutically acceptable excipients and carriers are known in the art.

Such pharmaceutical carriers and excipients as well as suitable pharmaceutical formulations

25 have been amply described in a variety of publications (see for example "Pharmaceutical Formulation Development of Peptides and Proteins", Frokjaer et al., Taylor & Francis (2000) or "Handbook of Pharmaceutical Excipients", 3rd edition, Kibbe et al., Pharmaceutical Press (2000) A. Gennaro (2000) "Remington: The Science and Practice of Pharmacy", 20th edition, Lippincott, Williams, & Wilkins; Pharmaceutical Dosage Forms and Drug Delivery Systems

30 (1999) H. C. Ansel et al., eds 7th ed., Lippincott, Williams, & Wilkins; and Handbook of Pharmaceutical Excipients (2000) A. H. Kibbe et al., eds., 3rd ed. Amer. Pharmaceutical Assoc). In particular, the pharmaceutical composition comprising the antibody of the invention may be formulated in lyophilized or stable soluble form. The polypeptide may be lyophilized by a variety of procedures known in the art. Lyophilized formulations are 35 reconstituted prior to use by the addition of one or more pharmaceutically acceptable diluents such as sterile water for injection or sterile physiological saline solution.

The pharmaceutical composition of the invention can be administered in dosages and by techniques well known in the art. The amount and timing of the administration will be determined by the treating physician or veterinarian to achieve the desired purposes. The

5 route of administration can be via any route that delivers a safe and therapeutically effective dose to the blood of the subject to be treated. Possible routes of administration include systemic, topical, enteral and parenteral routes, such as intravenous, intraarterial, subcutaneous, intradermal, intraperitoneal, oral, transmucosal, epidural, or intrathecal. Preferred routes are intravenous or subcutaneous.

10

The effective dosage and route of administration are determined by factors, such as age and weight of the subject, and by the nature and therapeutic range of the antibody or antigen-binding fragment thereof. The determination of the dosage is determined by known methods, no undue experimentation is required.

15

A therapeutically effective dose is a dose of the antibody or antigen binding fragment thereof of the invention that brings about a positive therapeutic effect in the patient or subject requiring the treatment. A therapeutically effective dose is in the range of about 0.01 to 50 mg/kg, from about 0.01 to 30 mg/kg, from about 0.1 to 30 mg/kg, from about 0.1 to 10 mg/kg, from about 0.1 to 5 mg/kg, from about 1 to 5 mg/kg, from about 0.1 to 2 mg/kg or from about 0.1 to 1 mg/kg. The treatment may comprise giving a single (e.g. bolus) dose or multiple doses. Alternatively continuous administration is possible. If multiple doses are required, they may be administered daily, every other day, weekly, biweekly, monthly, or bimonthly or as required. A depository may also be used that slowly and continuously releases the antibody or antigen-binding fragment thereof. A therapeutically effective dose may be a dose that inhibits GPV in the subject by at least 50%, preferably by at least 60%, 70%, 80%, 90%, more preferably by at least 95%, 99% or even 100%.

The antibody can be formulated as an aqueous solution.

30

Pharmaceutical compositions can be conveniently presented in unit dose forms containing a predetermined amount of a GPV inhibitor, e.g. an anti-GPV antibody, per dose. Such a unit can contain 0.5 mg to 5 g, for example, but without limitation, 1 mg, 10 mg, 20 mg, 30 mg, 40 mg, 50 mg, 100 mg, 200 mg, 300 mg, 400 mg, 500 mg, 750 mg, 1000 mg, or any range 35 between any two of the foregoing values, for example 10 mg to 1000 mg, 20 mg to 50 mg, or

30 mg to 300 mg. Pharmaceutically acceptable carriers can take a wide variety of forms depending, e.g. on the condition to be treated or route of administration.

Determination of the effective dosage, total number of doses and length of treatment with a

5 GPV inhibitor, e.g. an anti-GPV antibody, is well within the capabilities of those skilled in the art and can be determined using a standard dose escalation study.

Therapeutic formulations of the GPV inhibitors, e.g. the anti-GPV antibodies, suitable in the

methods described herein can be prepared for storage as lyophilized formulations or

10 aqueous solutions by mixing the inhibitor, e.g. the antibody, having the desired degree of purity with optional pharmaceutically-acceptable carriers, excipients or stabilizers typically employed in the art (all of which are referred to herein as "carriers"), i.e. buffering agents, stabilizing agents, preservatives, isotonifiers, non-ionic detergents, antioxidants and other miscellaneous additives. See, Remington's Pharmaceutical Sciences, 16th edition (Osol, ed. 15 1980). Such additives must be nontoxic to the recipients at the dosages and concentrations employed.

Buffering agents help to maintain the pH in the range which approximates physiological conditions. They can be present at concentrations ranging from about 2 mM to about 50 mM.

20 Suitable buffering agents include both organic and inorganic acids and salts thereof, such as citrate buffers (e.g. monosodium citrate-disodium citrate mixture, citric acid-trisodium citrate mixture, citric acid-monosodium citrate mixture, etc.), succinate buffers (e.g. succinic acid-monosodium succinate mixture, succinic acid-sodium hydroxide mixture, succinic acid-disodium succinate mixture, etc.), tartrate buffers (e.g. tartaric acid-sodium tartrate mixture, 25 tartaric acid-potassium tartrate mixture, tartaric acid-sodium hydroxide mixture, etc.), fumarate buffers (e.g. fumaric acid-monosodium fumarate mixture, fumaric acid-disodium fumarate mixture, monosodium fumarate-disodium fumarate mixture, etc.), gluconate buffers (e.g. gluconic acid-sodium gluconate mixture, gluconic acid-sodium hydroxide mixture, gluconic acid-potassium gluconate mixture, etc.), oxalate buffer (e.g. oxalic acid-sodium 30 oxalate mixture, oxalic acid-sodium hydroxide mixture, oxalic acid-potassium oxalate mixture, etc), lactate buffers (e.g. lactic acid-sodium lactate mixture, lactic acid-sodium hydroxide mixture, lactic acid-potassium lactate mixture, etc.) and acetate buffers (e.g. acetic acid-sodium acetate mixture, acetic acid-sodium hydroxide mixture). Additionally, phosphate buffers, histidine buffers and trimethylamine salts, such as Tris can be used.

Preservatives can be added to retard microbial growth, and can be added in amounts ranging from 0.2%-1% (w/v). Suitable preservatives include phenol, benzyl alcohol, metacresol, methyl paraben, propyl paraben, octadecyldimethylbenzyl ammonium chloride, benzalconium halides (e.g. chloride, bromide, and iodide), hexamethonium chloride, and

5 alkyl parabens, such as methyl or propyl paraben, catechol, resorcinol, cyclohexanol, and 3-pentanol. Isotonicifiers sometimes known as "stabilizers" can be added to ensure isotonicity of liquid compositions and include polyhydric sugar alcohols, preferably trihydric or higher sugar alcohols, such as glycerin, erythritol, arabinol, xylitol, sorbitol and mannitol. Stabilizers refer to a broad category of excipients, which can range in function from a bulking agent to
10 an additive, which solubilizes the therapeutic agent or helps to prevent denaturation or adherence to the container wall. Typical stabilizers can be polyhydric sugar alcohols (enumerated above); amino acids, such as arginine, lysine, glycine, glutamine, asparagine, histidine, alanine, ornithine, L-leucine, 2-phenylalanine, glutamic acid, threonine, etc., organic sugars or sugar alcohols, such as lactose, trehalose, stachyose, mannitol, sorbitol, xylitol,
15 ribitol, myoinisitol, galactitol, glycerol and the like, including cyclitols, such as inositol; polyethylene glycol; amino acid polymers; sulfur containing reducing agents, such as urea, glutathione, thioctic acid, sodium thioglycolate, thioglycerol, α -monothioglycerol and sodium thio sulfate; low molecular weight polypeptides (e.g. peptides of 10 residues or fewer); proteins, such as human serum albumin, bovine serum albumin, gelatin or immunoglobulins;
20 hydrophylic polymers, such as polyvinylpyrrolidone monosaccharides, such as xylose, mannose, fructose, glucose; disaccharides, such as lactose, maltose, sucrose and trisaccacharides, such as raffinose; and polysaccharides, such as dextran. Stabilizers can be present in the range from 0.1 to 10,000 weights per part of weight active protein.

25 Non-ionic surfactants or detergents (also known as "wetting agents") can be added to help solubilize the therapeutic agent as well as to protect the therapeutic protein against agitation-induced aggregation, which also permits the formulation to be exposed to shear surface stressed without causing denaturation of the protein. Suitable non-ionic surfactants include polysorbates (20, 80, etc.), polyoxamers (184, 188, etc.), pluronic polyols, polyoxyethylene
30 sorbitan monoethers (TWEEN®-20, TWEEN®-80, etc.). Non-ionic surfactants can be present in a range of about 0.05 mg/ml to about 1.0 mg/ml, or in a range of about 0.07 mg/ml to about 0.2 mg/ml.

35 Additional miscellaneous excipients include bulking agents (e.g. starch), chelating agents (e.g. EDTA), antioxidants (e.g. ascorbic acid, methionine, vitamin E), and co-solvents.

The formulation herein can also contain a second therapeutic agent in addition to a GPV inhibitor, e.g. an anti-GPV antibody. Examples of suitable second therapeutic agents are provided below.

5 The dosing schedule can vary from once a month to daily depending on a number of clinical factors, including the type of disease, severity of disease, and the patient's sensitivity to the GPV inhibitor, e.g. an anti-GPV antibody. In specific embodiments, a GPV inhibitor, e.g. an anti-GPV antibody, is administered daily, twice weekly, three times a week, every 5 days, every 10 days, every two weeks, every three weeks, every four weeks or once a month, or in
10 any range between any two of the foregoing values, for example from every four days to every month, from every 10 days to every two weeks, or from two to three times a week, etc. The dosage of a GPV inhibitor, e.g. an anti-GPV antibody, to be administered will vary according to the particular antibody, the subject, and the nature and severity of the disease, the physical condition of the subject, the therapeutic regimen (e.g. whether a second
15 therapeutic agent is used), and the selected route of administration; the appropriate dosage can be readily determined by a person skilled in the art.

It will be recognized by one of skill in the art that the optimal quantity and spacing of individual dosages of a GPV inhibitor, e.g. an anti-GPV antibody, will be determined by the
20 nature and extent of the condition being treated, the form, route and site of administration, and the age and condition of the particular subject being treated, and that a physician will ultimately determine appropriate dosages to be used. This dosage can be repeated as often as appropriate. If side effects develop, the amount and/or frequency of the dosage can be altered or reduced, in accordance with normal clinical practice.

25

Combination Therapy

Preferably, the patient being treated with the GPV inhibitor, e.g. an anti-GPV antibody, is also treated with conventional coagulants. For example, a patient suffering from excessive
30 bleeding is typically also being treated with an anti-fibrinolytic agent, a platelet concentrate, a coagulation factor concentrate and/or fresh frozen plasma.

Yet another aspect of the invention is the use of an inhibitor (preferably an antibody) as defined hereinabove for promoting hemostasis.

35

Yet another aspect of the invention is a compound (preferably an antibody) as defined hereinabove for use in reducing the bleeding time in a patient suffering from excessive bleeding.

5 The invention further relates to a method of reducing the bleeding time, comprising administering to a subject an effective amount of an inhibitor (preferably an antibody) as defined hereinabove.

A further aspect of this invention is a method of treating a hemorrhagic condition, comprising 10 administering to a patient in need thereof an effective amount of an inhibitor (preferably an antibody) as defined hereinabove. The hemorrhagic condition is preferably one of the conditions described above.

A further aspect of this invention is a method of preventing a hemorrhagic condition, 15 comprising administering to a patient in need thereof an effective amount of an inhibitor (preferably an antibody) as defined hereinabove. The hemorrhagic condition is preferably one of the conditions described above.

20 Overview of the nucleotide and amino acid sequences:

SEQ ID NO:	Description
1	Nucleic acid sequence encoding human GPV
2	Amino acid sequence encoded by SEQ ID NO:1, i.e. human GPV including signal peptide
3	Amino acid sequence of human GPV lacking signal peptide
4	Nucleic acid sequence encoding murine GPV
5	Amino acid sequence encoded by SEQ ID NO:4, i.e. murine GPV including signal peptide
6	Amino acid sequence of murine GPV lacking signal peptide

EXAMPLES

Results

89F12 is a monoclonal rat anti-mouse GPV antibody. It was generated by fusion of immortalized AG14 myeloma cells and spleen cells of rats, which were immunized with mouse platelets. 89F12 binds to wildtype, but not to GPV-deficient mouse platelets (Figure 1A) and 89F12 binds soluble GPV which is formed upon thrombin-cleavage of the receptor (Figure 1B). Moreover, 89F12 binds to the recombinantly expressed extracellular domain of murine GPV (Figure 1B).

10

In vivo, 89F12-IgG or 89F12-Fab fragments have no effect on the platelet count and have no influence on the thrombin-mediated cleavage of GPV (Figure 2 and data not shown). Furthermore, 89F12 does not affect platelet activation *in vitro* as assessed by flow cytometry (Figure 2D), aggregometry or flow adhesion assays (not shown). Of note it does not interfere 15 with the collagen-binding site of GPV as it does not delay collagen-induced aggregation (Fig. 3) – in contrast to 89H11, an anti-GPV antibody which blocks the collagen-binding site of GPV.

The effect of the anti-GPV antibody on hemostasis and thrombus formation was tested *in vivo*. Intravenous injection of 100 µg 89F12 in WT mice resulted in an accelerated time to 20 cessation of the blood loss in the tail bleeding time assay. Simultaneous depletion of GPVI and CLEC-2 by JAQ1- and INU1-injection, respectively, resulted in a pronounced hemostatic defect since 5 of 14 mice could not stop the bleeding within the observation period of 20 min. Blockade of the extracellular domain of GPV by 89F12 could compensate for the hemostatic 25 defect of GPVI/CLEC-2 double-depleted mice resulting in tail bleeding times in these mice comparable to 89F12-treated WT mice. This means that 89F12 can restore hemostasis in GPVI/CLEC-2 double-depleted mice. Thereby, 89F12 prevents hemostatic complications in the absence of GPVI and CLEC-2 (Figure 4). To test whether receptor dimerization or the Fc portion of the antibody are required for its effects on thrombus formation GPVI-depleted $\alpha 2$ - 30 deficient ($Itga2^{-/-}$) mice were treated with vehicle or 89F12-Fab fragments. Vehicle-treated GPVI-depleted $Itga2^{-/-}$ mice bled more than 20 min, while 89F12-Fab fragments restored the hemostatic function of these mice (Figure 5).

Since GPV blockade promotes hemostasis, thrombus formation was also studied in 89F12-treated mice. 89F12-treated mice displayed an accelerated time to thrombus formation *in vivo*. Depletion of the principal platelet activating collagen receptor GPVI using JAQ1 led to a

delayed thrombus formation time in WT mice and only 6 out of 13 vessels occluded within the observation period. Even in the absence of GPVI, 89F12-mediated blockade of GPV resulted in an earlier beginning of thrombus formation (data not shown) finally leading to a faster vessel occlusion even if compared to untreated WT controls ($P<0.001$, Figure 6).

5 89F12-mediated blockade of GPV could fully compensate for the lack of GPVI in *in vivo* thrombus formation and hemostasis.

The fact that GPV-blockade could counterbalance the absence of the (hem)ITAM receptors

GPVI and CLEC-2 suggests that GPV serves as a general negative regulator of platelet

10 activation. Therefore, we investigated whether GPV blockade could compensate for the absence of other critical signaling molecules.

Platelet activation upon vessel wall injury leads to cytoskeletal rearrangements which are

crucial for conversion from a discoid to a spheric platelet shape, for granule secretion and

15 spreading. The Rho family of small GTPases, such as RhoA, is thought to be involved in

many of these processes. RhoA plays a central role in the organization of the actin

cytoskeleton through the formation of stress fibers, the regulation of actomyosin contractility

and in the regulation of microtubule dynamics (Bustelo XR, et al. *BioEssays*. 2007; **29**: 356-

70). Furthermore, RhoA is involved in different cellular processes downstream of G_q- and

20 G₁₃-coupled agonist receptors (Pleines I, et al. *Blood*. 2012; **119**: 1054-63).

Megakaryocyte- and platelet specific RhoA-deficient mice displayed a pronounced

macrothrombocytopenia with reduction of platelet counts by 50% (Pleines I, et al. *Blood*.

2012; **119**: 1054-63). Lack of RhoA prolonged tail bleeding times (720 ± 321 s, compared to

25 430 ± 267 s in WT mice). In contrast, 89F12 treatment of RhoA-deficient mice could rescue

the hemostatic defect of *RhoA*^{fl/fl}, *PF4-cre* mice resulting in shortened tail bleeding times

compared to WT mice (286 ± 118 s for 89F12-treated RhoA-deficient mice, $P<0.01$

compared to RhoA-deficient mice, Figure 7). This indicated that antibody-mediated GPV-blockade can also compensate for the lack of critical downstream signaling molecules.

30

Thrombocytopenia is a critical risk factor for bleeding. To assess the role of GPV blockade under these conditions, thrombocytopenia was induced in mice by injection of two monoclonal anti-GPIba antibodies, which deplete circulating platelets in mice independently of immune effector mechanisms (Nieswandt B, et al. *Blood*. 2000; **96**: 2520-7; Bergmeier W,

35 et al. *Blood*. 2000; **95**: 886-93). Initial platelet counts were assessed as described above for each mouse and considered 100%. Subsequent counts were assessed 1 h after injection of

the antibody and were normalized to the initial values. Wildtype mice with platelet count reduction below 15% of normal displayed prolonged bleeding times or were unable to stop the bleeding within the observation period of 20 min. In contrast, platelet count reductions up to 5% of normal did not alter tail bleeding times compared to 89F12-treated mice having a normal platelet count, but showed significantly shortened tail bleeding times when compared to platelet-depleted WT-mice indicating that the blockade of GPV lowers the platelet count required to maintain normal hemostasis (not shown).

Materials and Methods

10 Mice

C57BL/6JRj (Janvier Labs) were used as wildtype control mice. Mice lacking GPV (*Gp5^{-/-}*), the α -2-integrin subunit (*Itga2^{-/-}*) were described previously (Kahn M. et al., *Blood* 1999; **94**: 4112-21; Holtkötter O. et al., *J Biol Chem.* 2002; **277**(13): 10789-94). Mice lacking RhoA in megakaryocytes/platelets (*RhoA^{fl/fl}, Ptf4-cre^{+/+}*) were described previously (Pleines I. et al., *Blood* 2012; **119**: 1054-63). GPVI was depleted by injecting 100 μ g of the anti-GPVI antibody, JAQ1 (Nieswandt B, et al. *J Exp Med.* 2001; **193**: 459-69.), i.p. 6 d before the experiment. CLEC-2 was depleted by i.p. injection of 200 μ g INU1 ((May F, et al. *Blood*. 2009; **114**: 3464-72); anti-CLEC-2 antibody). GPV blockade was achieved by injecting 50 μ g 89F12-IgG or Fab-fragments 30 min to 12 h before the experiment. Animal studies were approved by the district government of Lower Franconia (Bezirksregierung Unterfranken).

Monoclonal Antibodies

Generation of anti-GPV antibodies

Female Wistar rats, 6 to 8 weeks of age, were immunized repeatedly with mouse platelets.

25 The rat spleen cells were then fused with mouse myeloma cells (Ag14.653) and hybridomas were selected in HAT medium. Hybridomas secreting monoclonal antibodies (mAbs) directed against platelet surface antigens were identified by flow cytometry (see below). *Gp5^{-/-}* platelets were used as controls to test antibody specificity against GPV. Positive hybridomas were subcloned twice before large-scale production.

30

The further antibodies used are summarized in the following table.

Antibody	Internal Name	Antigen	Described in
INU1	11E9	CLEC-2	[7]
JAQ1	98A3	GPVI	[31]
p0p/B	57E12	GPIb	[33]

JON/A 4H5 GPIIb/IIIa Bergmeier et al., Cytometry 2002

Buffers and Media

All buffers were prepared with double-distilled water.

Phosphate buffered saline (PBS), pH 7.14

NaCl	137 mM
KCl	2.7 mM
KH ₂ PO ₄	1.5 mM
Na ₂ HPO ₄	8 mM

5

In vitro Platelet Analyses

Platelet Preparation and Washing

Mice were bled under isoflurane anesthesia from the retroorbital plexus. 700 µl blood were collected into a 1.5 ml reaction tube containing 300 µl heparin in TBS (20 U/ml, pH 7.3). Blood

10 was centrifuged at 800 rpm (52 g; in a Eppendorf Centrifuge 5415C) for 5 min at RT.

Supernatant and buffy coat were transferred into a new tube and centrifuged at 800 rpm for 6 min at RT to obtain *platelet rich plasma* (PRP). To prepare washed platelets, PRP was centrifuged at 2800 rpm (639 g) for 5 min at RT in the presence of *prostacyclin* (PGI₂) (0.1 µg/ml) and the pellet was resuspended in 1 ml Ca²⁺-free Tyrode's buffer containing PGI₂

15 (0.1 µg/ml) and apyrase (0.02 U/ml). After 10 min incubation at 37°C the sample was centrifuged at 2800 rpm for 5 min. After resuspending the platelets once more in 1 ml Ca²⁺-

free Tyrode's buffer, the platelet levels were determined taking a 1:10 dilution of the platelet solution and measuring platelet counts in a Sysmex counter (see below). The pellet was resuspended in the volume of Tyrode's buffer containing apyrase (0.02 U/ml) required to

20 obtain 500,000 platelets/µl and left to incubate for at least 30 min at 37°C before analysis.

For determination of platelet count and size, 50 µl blood were drawn from the retroorbital plexus of anesthetized mice using heparinized microcapillaries and collected into a 1.5 ml reaction tube containing 300 µl heparin in TBS (20 U/ml, pH 7.3). The heparinized blood was diluted with PBS and platelet counts and size were determined using a Sysmex KX-21N

25 automated hematology analyzer (Sysmex Corp., Kobe, Japan).

Flow Cytometry

For determination of glycoprotein expression levels, platelets (1*10⁶) were stained for 10 min at RT with saturating amounts of fluorophore-conjugated antibodies described above and

30 analyzed directly after addition of 500 µl PBS. The reaction was stopped by addition of 500 µl PBS and samples were analyzed on a FACSCalibur (Becton Dickinson, Heidelberg,

Germany). For platelet activation studies, washed blood was incubated with the indicated agonists in the presence of JON/A-PE and anti-P-selectin-FITC for 15 min.

ELISA

5 Washed platelets were prepared as described above and stimulated with 0.1 U/ml thrombin for 15 min at 37 °C. Afterwards, the platelet suspension was centrifuged for 5 min at 2800 rpm, the supernatant was transferred to a new reaction tube and once again centrifuged for 5 min at maximal speed. 100 µl of the thrombin-stimulated platelet supernatant were transferred to a 96-well plate which was previously coated with 30 µg 10 89H11 (anti-GPV antibody) and blocked with 5% BSA/PBS. After an incubation of 1 h, the 96-well plate was washed and incubated with HRP-labelled 89F12, a second anti-GPV antibody, to detect the cleaved GPV. The HRP substrate was developed using TMB, the reaction was stopped with H₂SO₄ and developed in an ELISA reader at 405 nm.

15 **Platelet Aggregation**

50 µl washed platelets (with a concentration of 0.5x10⁶ platelets/µl) or heparinized PRP was transferred into a cuvette containing 110 µl Tyrode's buffer (with 2 mM CaCl₂ and 100 µg/ml human fibrinogen). For determination of aggregation, antibodies were added to a final concentration of 10 µg/ml, agonists were added 100-fold concentrated and light transmission 20 was recorded over 10 min on an Apact 4-channel optical aggregation system (APACT, Hamburg, Germany). For calibration of each measurement before agonist addition Tyrode's buffer was set as 100% aggregation and washed platelet suspension or PRP was set as 0% aggregation.

25 ***In vivo* Analyses of Platelet Function**

Platelet depletion

Initial platelet counts were assessed as described above for each mouse. These values were considered 100% and subsequent counts were normalized to these values. Mice were 30 injected intravenously with 0.2 µg anti-GPIb antibodies per g mouse to induce an Fc-independent thrombocytopenia. Mice were injected 1 h before the experiment to achieve a remaining platelet count of 5-10% to induce Fc_YR-independent thrombocytopenia. 1 h after injection, platelet counts were again assessed.

Mechanical Injury of the Abdominal Aorta

To open the abdominal cavity of anesthetized mice (10-16 weeks of age), a longitudinal midline incision was performed and the abdominal aorta was exposed. A Doppler ultrasonic flow probe (Transonic Systems, Maastricht, Netherlands) was placed around the aorta and

5 thrombosis was induced by mechanical injury with a single firm compression (15 s) of a forceps upstream of the flow probe. Blood flow was monitored until complete occlusion occurred or 30 min had elapsed.

Bleeding Time Assay

10 Mice were anesthetized by intraperitoneal injection of triple anesthesia and a 2-mm segment of the tail tip was removed with a scalpel. Tail bleeding was monitored by gently absorbing blood with filter paper at 20 s intervals without directly contacting the wound site. When no blood was observed on the paper, bleeding was determined to have ceased. The experiment was manually stopped after 20 min by cauterization.

15

Statistical Analysis

Results are shown as mean \pm SD from at least three individual experiments per group. When applicable Fisher's exact test was used for statistical analysis. Otherwise, the Welch's *t* test was performed for statistical analysis. *P*-values <0.05 were considered statistically

20 significant.

5 Claims

1. An inhibitor of platelet glycoprotein V (GPV) for use as a coagulant.

2. An inhibitor of platelet glycoprotein V (GPV) for use in the treatment or prevention of a
10 hemorrhagic condition.

3. The inhibitor for use according to claim 2, wherein said hemorrhagic condition is caused
by a platelet disorder.

15 4. The inhibitor for use according to claim 3, wherein said platelet disorder is characterized
by a decreased number of platelets.

5. The inhibitor for use according to any one of claims 2 to 4, wherein said hemorrhagic
condition is selected from the group consisting of inflammatory bleeding, hemorrhagic
20 stroke, excessive bleeding due to sepsis, excessive bleeding due to thrombocytopenia,
excessive bleeding due to disseminated intravascular coagulation (DIC), excessive
bleeding due to chemotherapy, excessive bleeding due to hemolytic-uremic syndrome,
excessive bleeding upon administration of soluble GPV, and excessive bleeding due to
HIV infection.

25

6. The inhibitor for use according to any one of the preceding claims, wherein said GPV is
human GPV.

7. The inhibitor for use according to any one of the preceding claims, wherein said inhibitor
30 is an antibody directed against the extracellular domain of GPV, or a functional fragment
or derivative of an antibody, said fragment or derivative being capable of binding to the
extracellular domain of GPV.

8. The inhibitor for use according to claim 7, wherein said antibody, fragment or derivative
35 binds to a region of the extracellular domain of GPV which is different from the collagen-
binding site of GPV.

9. The inhibitor for use according to claim 7, wherein said antibody, fragment or derivative does not delay collagen-induced aggregation.

5 10. The inhibitor for use according to any one of claims 7 to 9, wherein said antibody is a monoclonal antibody or a functional fragment or functional derivative thereof.

11. The inhibitor for use according to any one of the preceding claims, wherein said inhibitor is a nucleic acid capable of reducing expression of GP5 mRNA.

10

12. The inhibitor for use according to any one of the preceding claims, wherein said inhibitor, upon administration to a subject, does not affect the number of platelets in said subject.

15

13. The inhibitor for use according to any one of claims 2 to 12, wherein said inhibitor is used as a coagulant.

14. The inhibitor for use according to any one of claims 2 to 13, wherein said treatment or prevention comprises administering to a subject, preferably to a human, a pharmaceutically effective amount of said inhibitor.

20

15. The inhibitor for use according to claim 14, wherein said treatment or prevention further comprises administering to said subject a coagulant other than said inhibitor.

25

16. The inhibitor for use according to claim 15, wherein said coagulant other than said inhibitor is selected from the group consisting of an anti-fibrinolytic agent, a platelet concentrate, a coagulation factor concentrate and fresh frozen plasma.

17. A pharmaceutical composition comprising an inhibitor as defined in any one of the preceding claims, and a pharmaceutically acceptable excipient.

30

18. A pharmaceutical composition as defined in claim 17 for use in the treatment or prevention of a hemorrhagic condition.

35

19. A method of treating a hemorrhagic condition in a subject, preferably a human, comprising administering to the subject an effective amount of an inhibitor as defined in any one of claims 1 to 13, or the pharmaceutical composition of claim 17.


Figure 1



Figure 2

Figure 3

2 μ g/ml Coll


Figure 4




Figure 5**Figure 6**

Figure 7

SEQUENCE LISTING

<110> Julius-Maximilians-Universität Würzburg
 <120> Glycoprotein VIIa inhibitors for use as coagulants
 <130> 2015_M003_A252
 <150> EP15202582.1
 <151> 2015-12-23
 <160> 6
 <170> PatentIn version 3.5
 <210> 1
 <211> 3493
 <212> DNA
 <213> Homo sapiens

 <220>
 <221> CDS
 <222> (32)..(1714)

 <400> 1
 agttactttg gagtgcagaa ccatttcaga c atg ctg agg ggg act cta ctg 52
 Met Leu Arg Gly Thr Leu Leu
 1 5

 tgc gcg gtg ctc ggg ctt ctg cgc gcc cag ccc ttc ccc tgt ccg cca 100
 Cys Ala Val Leu Gly Leu Leu Arg Ala Glu Pro Phe Pro Cys Pro Pro
 10 15 20

 gct tgc aag tgt gtc ttc cgg gac gcc gcg cag tgc tcg ggg ggc gac 148
 Ala Cys Lys Cys Val Phe Arg Asp Ala Ala Glu Cys Ser Gly Gly Asp
 25 30 35

 gtg gcg cgc atc tcc gcg cta ggc ctg ccc acc aac ctc acg cac atc 196
 Val Ala Arg Ile Ser Ala Leu Gly Leu Pro Thr Asn Leu Thr His Ile
 40 45 50 55

 ctg ctc ttc gga atg ggc cgc ggc gtc ctg cag agc cag agc ttc agc 244
 Leu Leu Phe Gly Met Gly Arg Glu Val Leu Glu Ser Glu Ser Phe Ser
 60 65 70

 ggc atg acc gtc ctg cag cgc ctc atg atc tcc gac agc cac att tcc 292
 Gly Met Thr Val Leu Glu Arg Leu Met Ile Ser Asp Ser His Ile Ser
 75 80 85

 gcc gtt gcc ccc ggc acc ttc agt gac ctg ata aaa ctg aaa acc ctg 340
 Ala Val Ala Pro Gly Thr Phe Ser Asp Leu Ile Lys Leu Lys Thr Leu
 90 95 100

 agg ctg tcg cgc aac aaa atc acg cat ctt cca ggt gcg ctg ctg gat 388
 Arg Leu Ser Arg Asn Lys Ile Thr His Leu Pro Gly Ala Leu Leu Asp
 105 110 115

 aag atg gtg ctc ctg gag cag ttg ttt ttg gac cac aat gcg cta agg 436
 Lys Met Val Leu Leu Gly Glu Leu Phe Leu Asp His Asn Ala Leu Arg
 120 125 130 135

 ggc att gac caa aac atg ttt cag aaa ctg gtt aac ctg cag gag ctc 484
 Gly Ile Asp Glu Asn Met Phe Glu Lys Leu Val Asn Leu Glu Leu
 140 145 150

 gct ctg aac cag aat cag ctc gat ttc ctt cct gcc agt ctc ttc acg 532
 Ala Leu Asn Glu Asn Glu Leu Asp Phe Leu Pro Ala Ser Leu Phe Thr

eol f-seql															
155	160	165													
aat ctg gag aac ctg aag ttg ttg gat tta tcg gga aac aac ctg acc															580
Asn Leu Glu Asn Leu Lys Leu Leu Asp Leu Ser Gly Asn Asn Leu Thr															
170 175 180															
cac ctg ccc aag ggg ttg ctt gga gca cag gct aag ctc gag aga ctt															628
His Leu Pro Lys Glu Leu Leu Glu Ala Glu Ala Lys Leu Glu Arg Leu															
185 190 195															
ctg ctc cac tcg aac cgc ctt gtg tct ctg gat tcg ggg ctg ttg aac															676
Leu Leu His Ser Asn Arg Leu Val Ser Leu Asp Ser Gly Leu Leu Asn															
200 205 210 215															
agc ctg ggc gcc ctg acg gag ctg cag ttc cac cga aat cac atc cgt															724
Ser Leu Glu Ala Leu Thr Glu Leu Glu Phe His Arg Asn His Ile Arg															
220 225 230															
tcc atc gca ccc ggg gcc ttc gac cgg ctc cca aac ctc agt tct ttg															772
Ser Ile Ala Pro Glu Ala Phe Asp Arg Leu Pro Asn Leu Ser Ser Leu															
235 240 245															
acg ctt tcg aga aac cac ctt gcg ttt ctc ccc tct gcg ctc ttt ctt															820
Thr Leu Ser Arg Asn His Leu Ala Phe Leu Pro Ser Ala Leu Phe Leu															
250 255 260															
cat tcg cac aat ctg act ctg ttg act ctg ttc gag aac ccg ctg gca															868
His Ser His Asn Leu Thr Leu Leu Thr Leu Phe Glu Asn Pro Leu Ala															
265 270 275															
gag ctc ccg ggg gtg ctc ttc ggg gag atg ggg ggc ctg cag gag ctg															916
Gl u Leu Pro Gl y Val Leu Phe Gl y Gl u Met Gl y Gl y Leu Gl n Gl u Leu															
280 285 290 295															
tgg ctg aac cgc acc cag ctg cgc acc ctg ccc gcc gcc gcc ttc cgc															964
Trp Leu Asn Arg Thr Gl n Leu Arg Thr Leu Pro Ala Ala Ala Phe Arg															
300 305 310															
aac ctg agc cgc ctg cgg tac tta ggg gtg act ctg agc ccg cgg ctg															1012
Asn Leu Ser Arg Leu Arg Tyr Leu Gl y Val Thr Leu Ser Pro Arg Leu															
315 320 325															
agc gcg ctt ccg cag ggc gcc ttc cag ggc ctt ggc gag ctc cag gtg															1060
Ser Ala Leu Pro Gl n Gl y Ala Phe Gl n Gl y Leu Gl y Gl u Leu Gl n Val															
330 335 340 345															
ctc gcc ctg cac tcc aac ggc ctg acc gcc ctc ccc gac ggc ttg ctg															1108
Leu Ala Leu His Ser Asn Gl y Leu Thr Ala Leu Pro Asp Gl y Leu Leu															
350 355															
cgc ggc ctc ggc aag ctg cgc cag gtg tcc ctg cgc cgc aac agg ctg															1156
Arg Gl y Leu Gl y Lys Leu Arg Gl n Val Ser Leu Arg Arg Asn Arg Leu															
360 365 370 375															
cgc gcc ctg ccc cgt gcc ctc ttc cgc aat ctc agc agc ctg gag agc															1204
Arg Ala Leu Pro Arg Ala Leu Phe Arg Asn Leu Ser Ser Leu Gl u Ser															
380 385 390															
gtc cag ctc gac cac aac cag ctg gag acc ctg cct ggc gac gtg ttt															1252
Val Gl n Leu Asp His Asn Gl n Leu Gl u Thr Leu Pro Gl y Asp Val Phe															
395 400 405															
ggg gct ctg ccc cgg ctg acg gag gtc ctg ttg ggg cac aac tcc tgg															1300
Gl y Ala Leu Pro Arg Leu Thr Gl u Val Leu Leu Gl y His Asn Ser Trp															
410 415 420															
cgc tgc gac tgt ggc ctg ggg ccc ttc ctg ggg tgg ctg cgg cag cac															1348
Arg Cys Asp Cys Gl y Leu Gl y Pro Phe Leu Gl y Trp Leu Arg Gl n His															

		eol f-seql		
425	430	435		
cta ggc ctc gtg ggc ggg gaa gag ccc cca cgg tgc gca ggc cct ggg				1396
Leu Gl y Leu Val Gl y Gl u Gl u Pro Pro Arg Cys Al a Gl y Pro Gl y	445	450	455	
Al a His Al a Gl y Leu Pro Leu Trp Al a Leu Pro Gl y Gl y Asp Al a Gl u	460	465	470	1444
tgc ccg ggc ccc cgg ggc ccg cct ccc cgc ccc gct gcg gac agc tcc				1492
Cys Pro Gl y Pro Arg Gl y Pro Pro Pro Arg Pro Al a Al a Asp Ser Ser	475	480	485	
tcg gaa gcc cct gtc cac cca gcc ttg gct ccc aac agc tca gaa ccc				1540
Ser Gl u Al a Pro Val His Pro Al a Leu Al a Pro Asn Ser Ser Gl u Pro	490	495	500	
tgg gtg tgg gcc cag ccg gtg acc acg ggc aaa ggt caa gat cat agt				1588
Trp Val Trp Al a Gl n Pro Val Thr Thr Gl y Lys Gl y Gl n Asp His Ser	505	510	515	
ccg ttc tgg ggg ttt tat ttt ctg ctt tta gct gtt cag gcc atg atc				1636
Pro Phe Trp Gl y Phe Tyr Phe Leu Leu Leu Al a Val Gl n Al a Met Ile	520	525	530	535
acc gtg atc atc gtg ttt gct atg att aaa att ggc caa ctc ttt cga				1684
Thr Val Ile Ile Val Phe Ala Met Ile Lys Ile Gl y Gl n Leu Phe Arg	540	545	550	
aaa tta atc aga gag aga gcc ctt ggg taa accaatggga aaatcttcta				1734
Lys Leu Ile Arg Gl u Arg Al a Leu Gl y	555	560		
attacttaga acctgaccag atgtggctcg gagggaaatc cagaccgcgt gctgtcttgc				1794
tctccctccc ctccccactc ctccctcttt cttccctttc tctctcactg ccacgccttc				1854
ctttccctcc tcctccccct ctccgctctg tgctcttcat tctcacaggg ccgcaacccc				1914
tcctctctgt gtcccccgcg cgttcctgga aactgagctt gacgtttgta aactgtggtt				1974
gcctgccttc cccagctccc acgggggtgt gcgcgtacac tgccgggggc gctggactgt				2034
gttggaccca tccgtgctcc gctgtgcctg gcttggcgtc tggtagagag agggccctct				2094
tcagtgtcta ctgatgttggggaa aggataggct gttgctctat ctaattttttt gttttgttt				2154
gtttgttgc tagctctgtg gcccaggctg gcgtgcgtg ggcgtctca gttcactgca				2214
gtttgttgc tagctctgtg gcccaggctg gcgtgcgtg ggcgtctca gttcactgca				2274
gtttgttgc tagctctgtg gcccaggctg gcgtgcgtg ggcgtctca gttcactgca				2334
gtttgttgc tagctctgtg gcccaggctg gcgtgcgtg ggcgtctca gttcactgca				2394
gtttgttgc tagctctgtg gcccaggctg gcgtgcgtg ggcgtctca gttcactgca				2454
gtttgttgc tagctctgtg gcccaggctg gcgtgcgtg ggcgtctca gttcactgca				2514
gtttgttgc tagctctgtg gcccaggctg gcgtgcgtg ggcgtctca gttcactgca				2574
gtttgttgc tagctctgtg gcccaggctg gcgtgcgtg ggcgtctca gttcactgca				2634
gtttgttgc tagctctgtg gcccaggctg gcgtgcgtg ggcgtctca gttcactgca				2694
gtttgttgc tagctctgtg gcccaggctg gcgtgcgtg ggcgtctca gttcactgca				2754

	eol f-seql				
tccctccagg tgcccagtgt aggtccagcg	tgtttctga	gcctcctgtg	agtttccact	2814	
tgcttacat ccatgcaaca	tgtcatttg	aaactggatt	gatttgcatt	2874	
ctgccacctc atttcacaag	cattatgga	gcagttaca	tgtgactgg	2934	
ataatgataa gcttgattct	agttcagctg	ctgtcacagt	ctcatttgg	2994	
aaagccgtaa aacctttgtt	gcttaattg	aatgtctgt	cttatgagag	gcagtggtt	3054
aaacagggc tggcgagttg	acaactgtgg	gttcaaatcc	cagctctacc	acttactaac	3114
tgcattggac tttgggtaag	acacctgctt	acattctcta	agccttgg	ttc	3174
taaaacagga taacatagta	cctgcttcgt	agagttttg	tgagaattaa	aggcaataaa	3234
gcatataatg acttagccca	gcggcctgca	ggcaatacat	gttaatgaat	gttagctatt	3294
attactaaag gatgagcaat	tattattggc	atcatgattt	ctaaagaaga	gctttgagtt	3354
ggtattttc tctgtgtata	aggtaagtc	cgaacttct	cagactggag	gttacattca	3414
catcagtctg tcttccctg	cgatggcct	cagccctgg	tgccagact	ctgtgctcac	3474
aatccagagc aatggatcc					3493

<210> 2

<211> 560

<212> PRT

<213> Homo sapiens

<400> 2

Met Leu Arg Gly Thr Leu Leu Cys Ala Val Leu Gly Leu Leu Arg Ala
 1 5 10 15

Gln Pro Phe Pro Cys Pro Pro Ala Cys Lys Cys Val Phe Arg Asp Ala
 20 25 30

Ala Gln Cys Ser Gly Gly Asp Val Ala Arg Ile Ser Ala Leu Gly Leu
 35 40 45

Pro Thr Asn Leu Thr His Ile Leu Leu Phe Gly Met Gly Arg Gly Val
 50 55 60

Leu Gln Ser Gln Ser Phe Ser Gly Met Thr Val Leu Gln Arg Leu Met
 65 70 75 80

Ile Ser Asp Ser His Ile Ser Ala Val Ala Pro Gly Thr Phe Ser Asp
 85 90 95

Leu Ile Lys Leu Lys Thr Leu Arg Leu Ser Arg Asn Lys Ile Thr His
 100 105 110

Leu Pro Gly Ala Leu Leu Asp Lys Met Val Leu Leu Glu Gln Leu Phe
 115 120 125

Leu Asp His Asn Ala Leu Arg Gly Ile Asp Gln Asn Met Phe Gln Lys
 130 135 140

eol f-seql

Leu Val Asn Leu Glu Leu Ala Leu Asn Glu Asn Glu Leu Asp Phe
145 150 155 160

Leu Pro Ala Ser Leu Phe Thr Asn Leu Glu Asn Leu Lys Leu Leu Asp
165 170 175

Leu Ser Gly Asn Asn Leu Thr His Leu Pro Lys Gly Leu Leu Gly Ala
180 185 190

Gln Ala Lys Leu Glu Arg Leu Leu Leu His Ser Asn Arg Leu Val Ser
195 200 205

Leu Asp Ser Gly Leu Leu Asn Ser Leu Gly Ala Leu Thr Glu Leu Gln
210 215 220

Phe His Arg Asn His Ile Arg Ser Ile Ala Pro Gly Ala Phe Asp Arg
225 230 235 240

Leu Pro Asn Leu Ser Ser Leu Thr Leu Ser Arg Asn His Leu Ala Phe
245 250 255

Leu Pro Ser Ala Leu Phe Leu His Ser His Asn Leu Thr Leu Leu Thr
260 265 270

Leu Phe Glu Asn Pro Leu Ala Glu Leu Pro Gly Val Leu Phe Gly Glu
275 280 285

Met Gly Gly Leu Gln Glu Leu Trp Leu Asn Arg Thr Gln Leu Arg Thr
290 295 300

Leu Pro Ala Ala Ala Phe Arg Asn Leu Ser Arg Leu Arg Tyr Leu Gly
305 310 315 320

Val Thr Leu Ser Pro Arg Leu Ser Ala Leu Pro Gln Gly Ala Phe Gln
325 330 335

Gly Leu Gly Glu Leu Gln Val Leu Ala Leu His Ser Asn Gly Leu Thr
340 345 350

Ala Leu Pro Asp Gly Leu Leu Arg Gly Leu Gly Lys Leu Arg Gln Val
355 360 365

Ser Leu Arg Arg Asn Arg Leu Arg Ala Leu Pro Arg Ala Leu Phe Arg
370 375 380

Asn Leu Ser Ser Leu Glu Ser Val Gln Leu Asp His Asn Gln Leu Glu
385 390 395 400

Thr Leu Pro Gly Asp Val Phe Gly Ala Leu Pro Arg Leu Thr Glu Val
405 410 415

eol f-seql

Leu Leu Gly His Asn Ser Trp Arg Cys Asp Cys Gly Leu Gly Pro Phe
420 425 430

Leu Gly Trp Leu Arg Gln His Leu Gly Leu Val Gly Gly Glu Glu Pro
435 440 445 450

Pro Arg Cys Ala Gly Pro Gly Ala His Ala Gly Leu Pro Leu Trp Ala
450 455 460

Leu Pro Gly Gly Asp Ala Glu Cys Pro Gly Pro Arg Gly Pro Pro Pro
465 470 475 480

Arg Pro Ala Ala Asp Ser Ser Ser Glu Ala Pro Val His Pro Ala Leu
485 490 495

Ala Pro Asn Ser Ser Glu Pro Trp Val Trp Ala Gln Pro Val Thr Thr
500 505 510

Gly Lys Gly Gln Asp His Ser Pro Phe Trp Gly Phe Tyr Phe Leu Leu
515 520 525

Leu Ala Val Gln Ala Met Ile Thr Val Ile Ile Val Phe Ala Met Ile
530 535 540

Lys Ile Gly Gln Leu Phe Arg Lys Leu Ile Arg Glu Arg Ala Leu Gly
545 550 555 560

<210> 3
<211> 544
<212> PRT
<213> Homo sapiens

<400> 3

Gln Pro Phe Pro Cys Pro Pro Ala Cys Lys Cys Val Phe Arg Asp Ala
1 5 10 15

Ala Gln Cys Ser Gly Gly Asp Val Ala Arg Ile Ser Ala Leu Gly Leu
20 25 30

Pro Thr Asn Leu Thr His Ile Leu Leu Phe Gly Met Gly Arg Gly Val
35 40 45

Leu Gln Ser Gln Ser Phe Ser Gly Met Thr Val Leu Gln Arg Leu Met
50 55 60

Ile Ser Asp Ser His Ile Ser Ala Val Ala Pro Gly Thr Phe Ser Asp
65 70 75 80

Leu Ile Lys Leu Lys Thr Leu Arg Leu Ser Arg Asn Lys Ile Thr His
85 90 95

eol f-seql

Leu Pro Gly Ala Leu Leu Asp Lys Met Val Leu Leu Glu Glu Leu Phe
100 105 110

Leu Asp His Asn Ala Leu Arg Gly Ile Asp Glu Asn Met Phe Glu Lys
115 120 125

Leu Val Asn Leu Glu Glu Leu Ala Leu Asn Glu Asn Glu Leu Asp Phe
130 135 140

Leu Pro Ala Ser Leu Phe Thr Asn Leu Glu Asn Leu Lys Leu Leu Asp
145 150 155 160

Leu Ser Gly Asn Asn Leu Thr His Leu Pro Lys Gly Leu Leu Gly Ala
165 170 175

Glu Ala Lys Leu Glu Arg Leu Leu Leu His Ser Asn Arg Leu Val Ser
180 185 190

Leu Asp Ser Gly Leu Leu Asn Ser Leu Gly Ala Leu Thr Glu Leu Glu
195 200 205

Phe His Arg Asn His Ile Arg Ser Ile Ala Pro Gly Ala Phe Asp Arg
210 215 220

Leu Pro Asn Leu Ser Ser Leu Thr Leu Ser Arg Asn His Leu Ala Phe
225 230 235 240

Leu Pro Ser Ala Leu Phe Leu His Ser His Asn Leu Thr Leu Thr
245 250 255

Leu Phe Glu Asn Pro Leu Ala Glu Leu Pro Gly Val Leu Phe Gly Glu
260 265 270

Met Gly Gly Leu Glu Glu Leu Trp Leu Asn Arg Thr Glu Leu Arg Thr
275 280 285

Leu Pro Ala Ala Ala Phe Arg Asn Leu Ser Arg Leu Arg Tyr Leu Gly
290 295 300

Val Thr Leu Ser Pro Arg Leu Ser Ala Leu Pro Glu Gly Ala Phe Glu
305 310 315 320

Gly Leu Gly Glu Leu Glu Val Leu Ala Leu His Ser Asn Gly Leu Thr
325 330 335

Ala Leu Pro Asp Gly Leu Leu Arg Gly Leu Gly Lys Leu Arg Glu Val
340 345 350

Ser Leu Arg Arg Asn Arg Leu Arg Ala Leu Pro Arg Ala Leu Phe Arg
355 360 365

eol f-seql

Asn Leu Ser Ser Leu Glu Ser Val Glu Leu Asp His Asn Glu Leu Glu
370 375 380

Thr Leu Pro Gly Asp Val Phe Gly Ala Leu Pro Arg Leu Thr Glu Val
385 390 395 400

Leu Leu Gly His Asn Ser Trp Arg Cys Asp Cys Gly Leu Gly Pro Phe
405 410 415

Leu Gly Trp Leu Arg Glu His Leu Gly Leu Val Gly Gly Glu Glu Pro
420 425 430

Pro Arg Cys Ala Gly Pro Gly Ala His Ala Gly Leu Pro Leu Trp Ala
435 440 445

Leu Pro Gly Gly Asp Ala Glu Cys Pro Gly Pro Arg Gly Pro Pro Pro
450 455 460

Arg Pro Ala Ala Asp Ser Ser Ser Glu Ala Pro Val His Pro Ala Leu
465 470 475 480

Ala Pro Asn Ser Ser Glu Pro Trp Val Trp Ala Glu Pro Val Thr Thr
485 490 495

Gly Lys Gly Glu Asp His Ser Pro Phe Trp Gly Phe Tyr Phe Leu Leu
500 505 510

Leu Ala Val Glu Ala Met Ile Thr Val Ile Ile Val Phe Ala Met Ile
515 520 525

Lys Ile Gly Glu Leu Phe Arg Lys Leu Ile Arg Glu Arg Ala Leu Gly
530 535 540

<210> 4

<211> 2215

<212> DNA

<213> Mus musculus

<220>

<221> CDS

<222> (30)..(1733)

<400> 4

tcagtccagg gtgcagaact gcttcagac atg cta aga agc gcc ctg ctg tcc
Met Leu Arg Ser Ala Leu Leu Ser
1 5

53

gcg gtg ctc gca ctc ttg cgt gcc caa cct ttt ccc tgc ccc aaa acc
Ala Val Leu Ala Leu Leu Arg Ala Glu Pro Phe Pro Cys Pro Lys Thr
10 15 20

101

tgc aag tgt gtg gtc cgc gat gcc gcg cag tgc tcg ggc ggc agc gtg
Cys Lys Cys Val Val Arg Asp Ala Ala Glu Cys Ser Gly Gly Ser Val
25 30 35 40

149

eol f-seql																
gct	cac	atc	gct	gag	cta	ggt	ctg	cct	acg	aac	ctc	aca	cac	atc	ctg	197
Ala	His	Ile	Ala	Gl u	Leu	Gly	Leu	Pro	Thr	Asn	Leu	Thr	His	Ile	Leu	
45								50							55	
ctc	tcc	cga	atg	gac	cag	ggc	ata	ttg	cgg	aac	cac	agc	ttc	agc	ggc	245
Leu	Phe	Arg	Met	Asp	Gl n	Gly	Ile	Leu	Arg	Asn	His	Ser	Phe	Ser	Gly	
60								65							70	
atg	aca	gtc	ctt	cag	cgc	ctg	atg	ctc	tca	gat	agc	cac	att	tcc	gcc	293
Met	Thr	Val	Leu	Gl n	Arg	Leu	Met	Leu	Ser	Asp	Ser	His	Ile	Ser	Ala	
75								80							85	
atc	gac	ccc	ggc	acc	tcc	aat	gac	ctg	gta	aaa	ctg	aaa	acc	ctc	agg	341
Ile	Asp	Pro	Gl y	Thr	Phe	Asn	Asp	Leu	Val	Lys	Leu	Lys	Thr	Leu	Arg	
90								95							100	
ttg	acg	cgc	aac	aaa	atc	tct	cgt	ctt	cca	cgt	gcg	atc	ctg	gat	aag	389
Leu	Thr	Arg	Asn	Lys	Ile	Ser	Arg	Leu	Pro	Arg	Ala	Ile	Leu	Asp	Lys	
105								110							115	
atg	gta	ctc	ttg	gaa	cag	ctg	ttc	ttg	gac	cac	aat	gca	cta	agg	gac	437
Met	Val	Leu	Leu	Gl u	Gl n	Leu	Phe	Leu	Asp	His	Asn	Ala	Leu	Arg	Asp	
								125							130	
ctt	gat	caa	aac	ctg	ttt	cag	caa	ctg	cgt	aac	ctt	cag	gag	ctc	gg t	485
Leu	Asp	Gl n	Asn	Leu	Phe	Gl n	Gl n	Leu	Arg	Asn	Leu	Gl n	Gl u	Leu	Gl y	
								140							145	
ttg	aac	cag	aat	cag	ctc	tct	ttt	ctt	cct	gct	aac	ctt	ttc	tcg	agc	533
Leu	Asn	Gl n	Asn	Gl n	Leu	Ser	Phe	Leu	Pro	Ala	Asn	Leu	Phe	Ser	Ser	
								155							160	
ctg	aga	gaa	ctg	aag	ttg	ttg	gat	tta	tcg	cga	aac	aac	ctg	acc	cac	581
Leu	Arg	Gl u	Leu	Lys	Leu	Leu	Asp	Leu	Ser	Arg	Asn	Asn	Leu	Thr	His	
								170							175	
ctg	ccc	aag	gga	ctg	ctt	ggg	gct	caa	gtt	aag	ctt	gag	aaa	ctg	ctg	629
Leu	Pro	Lys	Gl y	Leu	Leu	Gl y	Ala	Gl n	Val	Lys	Leu	Gl u	Lys	Leu	Leu	
								185							190	
ctc	tat	tca	aac	cag	ctc	acg	tct	gtg	gat	tcg	ggg	ctg	ctg	agc	aac	677
Leu	Tyr	Ser	Asn	Gl n	Leu	Thr	Ser	Val	Asp	Ser	Gl y	Leu	Leu	Ser	Asn	
								205							210	
ctg	ggc	gcc	ctg	act	gag	ctg	cgg	ctg	gag	cgg	aat	cac	ctc	cgc	tcc	725
Leu	Gl y	Ala	Leu	Thr	Gl u	Leu	Arg	Leu	Gl u	Arg	Asn	His	Leu	Arg	Ser	
								220							225	
gta	gcc	ccg	ggt	gcc	tcc	gac	cgc	ctc	gga	aac	ctg	agc	tcc	ttg	act	773
Val	Ala	Pro	Gl y	Ala	Phe	Asp	Arg	Leu	Gl y	Asn	Leu	Ser	Ser	Leu	Thr	
								235							240	
cta	tcc	gga	aac	ctc	ctg	gag	tct	ctg	ccg	ccc	gcg	ctc	ttc	ctt	cac	821
Leu	Ser	Gl y	Asn	Leu	Leu	Gl u	Ser	Leu	Pro	Pro	Ala	Leu	Phe	Leu	His	
								250							255	
gtg	agc	agc	gtg	tct	cgg	ctg	act	ctg	ttc	gag	aac	ccc	ctg	gag	gag	869
Val	Ser	Ser	Val	Ser	Arg	Leu	Thr	Leu	Phe	Gl u	Asn	Pro	Leu	Gl u	Gl u	
								265							270	
ctc	ccg	gac	gtg	ttg	tcc	ggg	gag	atg	gcc	ggc	ctg	cg g	gag	ctg	tgg	917
Leu	Pro	Asp	Val	Leu	Phe	Gly	Gl u	Met	Al a	Gl y	Leu	Arg	Gl u	Leu	Trp	
								285							290	
ctg	aac	ggc	acc	cac	ctg	agc	acg	ctg	ccc	gcc	gct	gcc	ttc	cgc	aac	965
Leu	Asn	Gl y	Thr	His	Leu	Ser	Thr	Leu	Pro	Al a	Al a	Al a	Phe	Arg	Asn	
								300							305	
															310	

eol f-seql

ctg	agc	ggc	ttg	cag	acg	ctg	ggg	ctg	acg	cg	aac	ccg	cgc	ctg	agc		1013
Leu	Ser	Gly	Leu	Gln	Thr	Leu	Gly	Leu	Thr	Arg	Asn	Pro	Arg	Leu	Ser		
315						320					325						
gcg	ctc	ccg	cgc	ggc	gtg	ttc	cag	ggc	cta	cg	gag	ctg	cgc	gtg	ctc		1061
Ala	Leu	Pro	Arg	Gly	Val	Phe	Gln	Gly	Leu	Arg	Glu	Leu	Arg	Val	Leu		
330					335					340							
gcg	ctg	cac	acc	aac	gcc	ctg	gcg	gag	ctg	cg	gac	gac	g	ctg	cgc		1109
Ala	Leu	His	Thr	Asn	Ala	Leu	Ala	Glu	Leu	Arg	Asp	Asp	Ala	Leu	Arg		
345				350					355						360		
ggc	ctc	ggg	cac	ctg	cgc	cag	gtg	tcg	ctg	cgc	cac	aac	cg	ctg	cgg		1157
Gly	Leu	Gly	His	Leu	Arg	Gln	Val	Ser	Leu	Arg	His	Asn	Arg	Leu	Arg		
						365			370				375				
gcc	ctg	ccc	cgc	acg	ctc	ttc	cgc	aac	ctc	agc	agc	ctc	gag	agc	gtg		1205
Ala	Leu	Pro	Arg	Thr	Leu	Phe	Arg	Asn	Leu	Ser	Ser	Leu	Glu	Ser	Val		
				380		385						390					
cag	cta	gag	cac	aac	cag	ctg	gag	acg	ctg	cca	gga	gac	gtg	ttc	g		1253
Gln	Leu	Glu	His	Asn	Gln	Leu	Glu	Thr	Leu	Pro	Gly	Asp	Val	Phe	Ala		
				395		400					405						
gct	ctg	ccc	cag	ctg	acc	cag	gtc	ctg	ctg	ggt	cac	aac	ccc	tgg	ctc		1301
Ala	Leu	Pro	Gln	Leu	Thr	Gln	Val	Leu	Leu	Gly	His	Asn	Pro	Trp	Leu		
				410		415				420							
tgc	gac	tgt	ggc	ctg	tgg	ccc	ttc	ctc	cag	tgg	ctg	cg	cat	cac	ccg		1349
Cys	Asp	Cys	Gly	Leu	Trp	Pro	Phe	Leu	Gln	Trp	Leu	Arg	His	His	Pro		
				425		430				435				440			
gac	atc	ctg	ggc	cga	gac	gag	ccc	ccg	cag	tgc	cgt	ggc	ccg	gag	cca		1397
Asp	Ile	Leu	Gly	Arg	Asp	Glu	Pro	Pro	Gln	Cys	Arg	Gly	Pro	Glu	Pro		
				445		450				455							
cgc	gcc	agc	ctg	tcg	ttc	tgg	gag	ctg	ctg	cag	ggt	gac	ccg	tgg	tgc		1445
Arg	Ala	Ser	Leu	Ser	Phe	Trp	Glu	Leu	Leu	Gln	Gly	Asp	Pro	Trp	Cys		
				460		465				470							
ccg	gat	cct	cgc	agc	ctg	cct	ctc	gac	cct	cca	acc	gaa	aat	gct	ctg		1493
Pro	Asp	Pro	Arg	Ser	Leu	Pro	Leu	Asp	Pro	Pro	Thr	Glu	Asn	Ala	Leu		
				475		480				485							
gaa	gcc	ccg	gtt	ccg	tcc	tgg	ctg	cct	aac	agc	tgg	cag	tcc	cag	acg		1541
Glu	Ala	Pro	Val	Pro	Ser	Trp	Leu	Pro	Asn	Ser	Trp	Gln	Ser	Gln	Thr		
				490		495				500							
tgg	gcc	cag	ctg	gtg	gcc	agg	ggt	gaa	agt	ccc	aat	aac	agg	ctc	tac		1589
Trp	Ala	Gln	Leu	Val	Ala	Arg	Gly	Glu	Ser	Pro	Asn	Asn	Arg	Leu	Tyr		
				505		510				515				520			
tgg	ggt	ctt	tat	att	ctg	ttt	cta	gta	gcc	cag	gcc	atc	ata	gcc	g		1637
Trp	Gly	Leu	Tyr	Ile	Leu	Leu	Leu	Val	Ala	Gln	Ala	Ile	Ile	Ala	Ala		
				525		530				535							
ttc	atc	gtg	ttt	gcc	atg	att	aaa	atc	ggc	cag	ctg	ttt	cga	aca	tta		1685
Phe	Ile	Val	Phe	Ala	Met	Ile	Lys	Ile	Gly	Gly	Gln	Leu	Phe	Arg	Thr	Leu	
				540		545				550							
atc	aga	gag	aag	ctc	ttg	tta	gag	gca	atg	gga	aaa	tcg	tgt	aac	taa		1733
Ile	Arg	Glu	Lys	Leu	Leu	Leu	Glu	Ala	Met	Gly	Lys	Ser	Cys	Asn			
				555		560				565							
tgaaaactgac	cagagcattg	tggacggggc	cccaaggaga	atgcagtcag	gatgctggcg											1793	
tgccattaca	ctatccca	ggccctttct	cctctccgt	gctcttagt	tctcttcttc											1853	

eol f-seql

tcccctctct	tcagaagtag	ctttgtaaa	tcgctactgc	tttctagcct	ggcctgggtt	1913
acctcctctg	ctgttagttt	caagggggct	gagggtgggg	gttcgacggg	acttggctca	1973
tcaggtccaa	ctgtcagcg	ctgggtgcct	agtggagaga	ggagccctt	cttggttct	2033
gaatttgggg	acacatcctg	ccagtggca	agacctctcc	gggacccagc	aagggtttag	2093
taacatttgc	tgaaggaaca	ccgcttaaa	acgaacccta	ggtccaagag	atgaaggctc	2153
ttcccaaaat	aaaggtggag	tgttcttgc	ccttacctg	aaaggaaaaaa	aaaaaaaaaa	2213
aa						2215

<210> 5
 <211> 567
 <212> PRT
 <213> Mus musculus

<400> 5

Met Leu Arg Ser Ala Leu Leu Ser Ala Val Leu Ala Leu Leu Arg Ala
 1 5 10 15

Glu Pro Phe Pro Cys Pro Lys Thr Cys Lys Cys Val Val Arg Asp Ala
 20 25 30

Ala Glu Cys Ser Gly Gly Ser Val Ala His Ile Ala Glu Leu Gly Leu
 35 40 45

Pro Thr Asn Leu Thr His Ile Leu Leu Phe Arg Met Asp Glu Gly Ile
 50 55 60

Leu Arg Asn His Ser Phe Ser Gly Met Thr Val Leu Glu Arg Leu Met
 65 70 75 80

Leu Ser Asp Ser His Ile Ser Ala Ile Asp Pro Gly Thr Phe Asn Asp
 85 90 95

Leu Val Lys Leu Lys Thr Leu Arg Leu Thr Arg Asn Lys Ile Ser Arg
 100 105 110

Leu Pro Arg Ala Ile Leu Asp Lys Met Val Leu Leu Glu Glu Leu Phe
 115 120 125

Leu Asp His Asn Ala Leu Arg Asp Leu Asp Glu Asn Leu Phe Glu Glu
 130 135 140

Leu Arg Asn Leu Glu Glu Leu Gly Leu Asn Glu Asn Glu Leu Ser Phe
 145 150 155 160

Leu Pro Ala Asn Leu Phe Ser Ser Leu Arg Glu Leu Lys Leu Leu Asp
 165 170 175

Leu Ser Arg Asn Asn Leu Thr His Leu Pro Lys Glu Leu Leu Glu Ala
 180 185 190

eol f-seql

Gl n Val Lys Leu Gl u Lys Leu Leu Leu Tyr Ser Asn Gl n Leu Thr Ser
195 200 205

Val Asp Ser Gl y Leu Leu Ser Asn Leu Gl y Al a Leu Thr Gl u Leu Arg
210 215 220

Leu Gl u Arg Asn His Leu Arg Ser Val Al a Pro Gl y Al a Phe Asp Arg
225 230 235 240

Leu Gl y Asn Leu Ser Ser Leu Thr Leu Ser Gl y Asn Leu Leu Gl u Ser
245 250 255

Leu Pro Pro Al a Leu Phe Leu His Val Ser Ser Val Ser Arg Leu Thr
260 265 270

Leu Phe Gl u Asn Pro Leu Gl u Gl u Leu Pro Asp Val Leu Phe Gl y Gl u
275 280 285

Met Al a Gl y Leu Arg Gl u Leu Trp Leu Asn Gl y Thr His Leu Ser Thr
290 295 300

Leu Pro Al a Al a Al a Phe Arg Asn Leu Ser Gl y Leu Gl n Thr Leu Gl y
305 310 315 320

Leu Thr Arg Asn Pro Arg Leu Ser Al a Leu Pro Arg Gl y Val Phe Gl n
325 330 335

Gl y Leu Arg Gl u Leu Arg Val Leu Al a Leu His Thr Asn Al a Leu Al a
340 345 350

Gl u Leu Arg Asp Asp Al a Leu Arg Gl y Leu Gl y His Leu Arg Gl n Val
355 360 365

Ser Leu Arg His Asn Arg Leu Arg Al a Leu Pro Arg Thr Leu Phe Arg
370 375 380

Asn Leu Ser Ser Leu Gl u Ser Val Gl n Leu Gl u His Asn Gl n Leu Gl u
385 390 395 400

Thr Leu Pro Gl y Asp Val Phe Al a Al a Leu Pro Gl n Leu Thr Gl n Val
405 410 415

Leu Leu Gl y His Asn Pro Trp Leu Cys Asp Cys Gl y Leu Trp Pro Phe
420 425 430

Leu Gl n Trp Leu Arg His His Pro Asp Ile Leu Gl y Arg Asp Gl u Pro
435 440 445

Pro Gl n Cys Arg Gl y Pro Gl u Pro Arg Al a Ser Leu Ser Phe Trp Gl u
450 455 460

eol f-seql

Leu Leu Glu Glu Asp Pro Trp Cys Pro Asp Pro Arg Ser Leu Pro Leu
465 470 475 480

Asp Pro Pro Thr Glu Asn Ala Leu Glu Ala Pro Val Pro Ser Trp Leu
485 490 495

Pro Asn Ser Trp Glu Ser Glu Thr Trp Ala Glu Leu Val Ala Arg Glu
500 505 510

Glu Ser Pro Asn Asn Arg Leu Tyr Trp Glu Leu Tyr Ile Leu Leu Leu
515 520 525

Val Ala Glu Ala Ile Ile Ala Ala Phe Ile Val Phe Ala Met Ile Lys
530 535 540

Ile Glu Glu Leu Phe Arg Thr Leu Ile Arg Glu Lys Leu Leu Leu Glu
545 550 555 560

Ala Met Glu Lys Ser Cys Asn
565

<210> 6

<211> 551

<212> PRT

<213> Mus musculus

<400> 6

Glu Pro Phe Pro Cys Pro Lys Thr Cys Lys Cys Val Val Arg Asp Ala
1 5 10 15

Ala Glu Cys Ser Glu Glu Ser Val Ala His Ile Ala Glu Leu Glu Leu
20 25 30

Pro Thr Asn Leu Thr His Ile Leu Leu Phe Arg Met Asp Glu Glu Ile
35 40 45

Leu Arg Asn His Ser Phe Ser Glu Met Thr Val Leu Glu Arg Leu Met
50 55 60

Leu Ser Asp Ser His Ile Ser Ala Ile Asp Pro Glu Thr Phe Asn Asp
65 70 75 80

Leu Val Lys Leu Lys Thr Leu Arg Leu Thr Arg Asn Lys Ile Ser Arg
85 90 95

Leu Pro Arg Ala Ile Leu Asp Lys Met Val Leu Leu Glu Glu Leu Phe
100 105 110

Leu Asp His Asn Ala Leu Arg Asp Leu Asp Glu Asn Leu Phe Glu Glu
115 120 125

eol f-seql

Leu Arg Asn Leu Glu Leu Glu Leu Asn Glu Asn Glu Leu Ser Phe
130 135 140

Leu Pro Ala Asn Leu Phe Ser Ser Leu Arg Glu Leu Lys Leu Leu Asp
145 150 155 160

Leu Ser Arg Asn Asn Leu Thr His Leu Pro Lys Glu Leu Leu Glu Ala
165 170 175

Glu Val Lys Leu Glu Lys Leu Leu Leu Tyr Ser Asn Glu Leu Thr Ser
180 185 190

Val Asp Ser Glu Leu Leu Ser Asn Leu Glu Ala Leu Thr Glu Leu Arg
195 200 205

Leu Glu Arg Asn His Leu Arg Ser Val Ala Pro Glu Ala Phe Asp Arg
210 215 220

Leu Glu Asn Leu Ser Ser Leu Thr Leu Ser Glu Asn Leu Leu Glu Ser
225 230 235 240

Leu Pro Pro Ala Leu Phe Leu His Val Ser Ser Val Ser Arg Leu Thr
245 250 255

Leu Phe Glu Asn Pro Leu Glu Glu Leu Pro Asp Val Leu Phe Glu Glu
260 265 270

Met Ala Glu Leu Arg Glu Leu Trp Leu Asn Glu Thr His Leu Ser Thr
275 280 285

Leu Pro Ala Ala Ala Phe Arg Asn Leu Ser Glu Leu Glu Thr Leu Glu
290 295 300

Leu Thr Arg Asn Pro Arg Leu Ser Ala Leu Pro Arg Glu Val Phe Glu
305 310 315 320

Glu Leu Arg Glu Leu Arg Val Leu Ala Leu His Thr Asn Ala Leu Ala
325 330 335

Glu Leu Arg Asp Asp Ala Leu Arg Glu Leu Glu His Leu Arg Glu Val
340 345 350

Ser Leu Arg His Asn Arg Leu Arg Ala Leu Pro Arg Thr Leu Phe Arg
355 360 365

Asn Leu Ser Ser Leu Glu Ser Val Glu Leu Glu His Asn Glu Leu Glu
370 375 380

Thr Leu Pro Glu Asp Val Phe Ala Ala Leu Pro Glu Leu Thr Glu Val
385 390 395 400

eol f-seql

Leu Leu Gly His Asn Pro Trp Leu Cys Asp Cys Gly Leu Trp Pro Phe
405 410 415

Leu Gln Trp Leu Arg His His Pro Asp Ile Leu Gly Arg Asp Glu Pro
420 425 430

Pro Gln Cys Arg Gly Pro Glu Pro Arg Ala Ser Leu Ser Phe Trp Glu
435 440 445

Leu Leu Gln Gly Asp Pro Trp Cys Pro Asp Pro Arg Ser Leu Pro Leu
450 455 460

Asp Pro Pro Thr Glu Asn Ala Leu Glu Ala Pro Val Pro Ser Trp Leu
465 470 475 480

Pro Asn Ser Trp Gln Ser Gln Thr Trp Ala Gln Leu Val Ala Arg Gly
485 490 495

Gl u Ser Pro Asn Asn Arg Leu Tyr Trp Gly Leu Tyr Ile Leu Leu Leu
500 505 510

Val Ala Gln Ala Ile Ile Ala Ala Phe Ile Val Phe Ala Met Ile Lys
515 520 525

Ile Gly Gln Leu Phe Arg Thr Leu Ile Arg Glu Lys Leu Leu Leu Gl u
530 535 540

Ala Met Gly Lys Ser Cys Asn
545 550